Raras
Buscar doenças, sintomas, genes...
Doença de Charcot-Marie-Tooth/neuropatia sensitiva e motora hereditária
ORPHA:166CID-11 · 8C20DOENÇA RARA

Doença degenerativa hereditária que envolve os nervos periféricos. É causada por mutações nos genes responsáveis ​​pela produção de proteínas necessárias ao funcionamento e estrutura dos nervos periféricos. É caracterizada por atrofia muscular e fraqueza nos pés, pernas, mãos e braços e perda de sensibilidade nos membros.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Doença degenerativa hereditária que envolve os nervos periféricos. É causada por mutações nos genes responsáveis ​​pela produção de proteínas necessárias ao funcionamento e estrutura dos nervos periféricos. É caracterizada por atrofia muscular e fraqueza nos pés, pernas, mãos e braços e perda de sensibilidade nos membros.

Medicamentos
6 registrados
NALTREXONE HYDROCHLORIDE, NALTREXONE, BACLOFEN

Tem tratamento?

6 medicamentos registrados
Ver detalhes, fases e interações →
NALTREXONE HYDROCHLORIDENALTREXONEBACLOFENULIPRISTAL ACETATEMEXILETINEEPALRESTAT

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-5 / 10 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
25.0
Europe
Início
All ages
🏥
SUS: Sem cobertura SUSScore: 0%
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

💪
Músculos
73 sintomas
🧠
Neurológico
57 sintomas
🦴
Ossos e articulações
34 sintomas
👁️
Olhos
21 sintomas
😀
Face
11 sintomas
👂
Ouvidos
9 sintomas

+ 196 sintomas em outras categorias

Características mais comuns

Desmielinização periférica
Amiotrofia extensora do dedo do pé
Atrofia muscular da cintura pélvica
Flexão limitada do joelho
Comprometimento da memória
Dispneia
423sintomas
Sem dados (423)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 423 características clínicas mais associadas, ordenadas por frequência.

Desmielinização periféricaPeripheral demyelination
Amiotrofia extensora do dedo do péToe extensor amyotrophy
Atrofia muscular da cintura pélvicaPelvic girdle muscle atrophy
Flexão limitada do joelhoLimited knee flexion
Comprometimento da memóriaMemory impairment

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Últimos 10 anos200publicações
Pico2025128 papers
Linha do tempo
2026Hoje · 2026🧪 2001Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

54 genes identificados com associação a esta condição. Padrão de herança: Autosomal dominant, Autosomal recessive, X-linked dominant, X-linked recessive.

PMP22Peroxisomal membrane protein 2Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Seems to be involved in pore-forming activity and may contribute to the unspecific permeability of the peroxisomal membrane

LOCALIZAÇÃO

Peroxisome membrane

VIAS BIOLÓGICAS (1)
EGR2 and SOX10-mediated initiation of Schwann cell myelination
EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
3229.9 TPM
Tecido adiposo
421.5 TPM
Cervix Ectocervix
415.8 TPM
Fallopian Tube
379.8 TPM
Cervix Endocervix
354.6 TPM
OUTRAS DOENÇAS (7)
Roussy-Levy syndromeCharcot-Marie-Tooth disease type 3hereditary neuropathy with liability to pressure palsiesCharcot-Marie-Tooth disease type 1E
HGNC:9118UniProt:Q9NR77
KARS1Lysine--tRNA ligaseCandidate gene tested inTolerante
FUNÇÃO

Catalyzes the specific attachment of an amino acid to its cognate tRNA in a 2 step reaction: the amino acid (AA) is first activated by ATP to form AA-AMP and then transferred to the acceptor end of the tRNA (PubMed:18029264, PubMed:18272479, PubMed:9278442). When secreted, acts as a signaling molecule that induces immune response through the activation of monocyte/macrophages (PubMed:15851690). Catalyzes the synthesis of the signaling molecule diadenosine tetraphosphate (Ap4A), and thereby media

LOCALIZAÇÃO

Cytoplasm, cytosolCytoplasmNucleusCell membraneSecretedMitochondrion

VIAS BIOLÓGICAS (3)
Selenoamino acid metabolismCytosolic tRNA aminoacylationTranscriptional and post-translational regulation of MITF-M expression and activity
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, recessive intermediate B

A form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Recessive intermediate forms of Charcot-Marie-Tooth disease are characterized by clinical and pathologic features intermediate between demyelinating and axonal peripheral neuropathies, and motor median nerve conduction velocities ranging from 25 to 45 m/sec.

OUTRAS DOENÇAS (7)
autosomal recessive nonsyndromic hearing loss 89Charcot-Marie-Tooth disease recessive intermediate Bdeafness, congenital, and adult-onset progressive leukoencephalopathyleukoencephalopathy, progressive, infantile-onset, with or without deafness
HGNC:6215UniProt:Q15046
VCPTransitional endoplasmic reticulum ATPaseCandidate gene tested inAltamente restrito
FUNÇÃO

Necessary for the fragmentation of Golgi stacks during mitosis and for their reassembly after mitosis. Involved in the formation of the transitional endoplasmic reticulum (tER). The transfer of membranes from the endoplasmic reticulum to the Golgi apparatus occurs via 50-70 nm transition vesicles which derive from part-rough, part-smooth transitional elements of the endoplasmic reticulum (tER). Vesicle budding from the tER is an ATP-dependent process. The ternary complex containing UFD1, VCP and

LOCALIZAÇÃO

Cytoplasm, cytosolEndoplasmic reticulumNucleusCytoplasm, Stress granule

VIAS BIOLÓGICAS (10)
AggrephagyAttachment and EntryAttachment and EntryAMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274)ABC-family proteins mediated transport
MECANISMO DE DOENÇA

Inclusion body myopathy with early-onset Paget disease with or without frontotemporal dementia 1

An autosomal dominant disease characterized by disabling muscle weakness clinically resembling to limb girdle muscular dystrophy, osteolytic bone lesions consistent with Paget disease, and premature frontotemporal dementia. Clinical features show incomplete penetrance.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
229.2 TPM
Linfócitos
209.1 TPM
Músculo esquelético
193.2 TPM
Aorta
172.4 TPM
Útero
171.2 TPM
OUTRAS DOENÇAS (10)
frontotemporal dementia and/or amyotrophic lateral sclerosis 6inclusion body myopathy with Paget disease of bone and frontotemporal dementia type 1Charcot-Marie-Tooth disease type 2Yamyotrophic lateral sclerosis
HGNC:12666UniProt:P55072
MMENeprilysinCandidate gene tested inTolerante
FUNÇÃO

Thermolysin-like specificity, but is almost confined on acting on polypeptides of up to 30 amino acids (PubMed:15283675, PubMed:6208535, PubMed:6349683, PubMed:8168535). Biologically important in the destruction of opioid peptides such as Met- and Leu-enkephalins by cleavage of a Gly-Phe bond (PubMed:17101991, PubMed:6349683). Catalyzes cleavage of bradykinin, substance P and neurotensin peptides (PubMed:6208535). Able to cleave angiotensin-1, angiotensin-2 and angiotensin 1-9 (PubMed:15283675,

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (4)
Metabolism of Angiotensinogen to AngiotensinsPhysiological factorsNeutrophil degranulationDevelopmental Lineage of Mammary Gland Myoepithelial Cells
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, axonal, type 2T

An axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy.

EXPRESSÃO TECIDUAL(Tecido-específico)
Fibroblastos
640.5 TPM
Nervo tibial
42.9 TPM
Rim - Córtex
37.7 TPM
Próstata
24.8 TPM
Tecido adiposo
24.0 TPM
OUTRAS DOENÇAS (5)
Charcot-Marie-Tooth disease axonal type 2Tspinocerebellar ataxia 43congenital membranous nephropathy due to maternal anti-neutral endopeptidase alloimmunizationCharcot-Marie-Tooth disease type 2T
HGNC:7154UniProt:P08473
PDK3[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrialCandidate gene tested inRestrito
FUNÇÃO

Inhibits pyruvate dehydrogenase activity by phosphorylation of the E1 subunit PDHA1, and thereby regulates glucose metabolism and aerobic respiration. Can also phosphorylate PDHA2. Decreases glucose utilization and increases fat metabolism in response to prolonged fasting, and as adaptation to a high-fat diet. Plays a role in glucose homeostasis and in maintaining normal blood glucose levels in function of nutrient levels and under starvation. Plays a role in the generation of reactive oxygen sp

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (2)
Signaling by Retinoic AcidRegulation of pyruvate dehydrogenase (PDH) complex
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, X-linked dominant, 6

A form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies characterized by severely reduced motor nerve conduction velocities (NCVs) (less than 38m/s) and segmental demyelination and remyelination, and primary peripheral axonal neuropathies characterized by normal or mildly reduced NCVs and chronic axonal degeneration and regeneration on nerve biopsy.

EXPRESSÃO TECIDUAL(Ubíquo)
Artéria tibial
33.5 TPM
Linfócitos
32.3 TPM
Aorta
27.0 TPM
Testículo
19.6 TPM
Sangue
16.1 TPM
OUTRAS DOENÇAS (1)
Charcot-Marie-Tooth disease X-linked dominant 6
HGNC:8811UniProt:Q15120
DNAJB2DnaJ homolog subfamily B member 2Candidate gene tested inTolerante
FUNÇÃO

Functions as a co-chaperone, regulating the substrate binding and activating the ATPase activity of chaperones of the HSP70/heat shock protein 70 family (PubMed:22219199, PubMed:7957263). In parallel, also contributes to the ubiquitin-dependent proteasomal degradation of misfolded proteins (PubMed:15936278, PubMed:21625540). Thereby, may regulate the aggregation and promote the functional recovery of misfolded proteins like HTT, MC4R, PRKN, RHO and SOD1 and be crucial for many biological process

LOCALIZAÇÃO

CytoplasmNucleusEndoplasmic reticulum membrane

MECANISMO DE DOENÇA

Neuronopathy, distal hereditary motor, autosomal recessive 5

A form of distal hereditary motor neuronopathy, a heterogeneous group of neuromuscular disorders caused by selective degeneration of motor neurons in the anterior horn of the spinal cord, without sensory deficit in the posterior horn. The overall clinical picture consists of a classical distal muscular atrophy syndrome in the legs without clinical sensory loss. The disease starts with weakness and wasting of distal muscles of the anterior tibial and peroneal compartments of the legs. Later on, weakness and atrophy may expand to the proximal muscles of the lower limbs and/or to the distal upper limbs. HMNR5 is characterized by young adult onset of slowly progressive distal muscle weakness and atrophy resulting in gait impairment and loss of reflexes.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Spinal cord cervical c-1
243.3 TPM
Cerebelo
240.3 TPM
Cérebro - Hemisfério cerebelar
230.7 TPM
Nervo tibial
157.6 TPM
Pituitária
147.9 TPM
OUTRAS DOENÇAS (2)
neuronopathy, distal hereditary motor, autosomal recessive 5Charcot-Marie-Tooth disease axonal type 2T
HGNC:5228UniProt:P25686
TRIM2Tripartite motif-containing protein 2Candidate gene tested inAltamente restrito
FUNÇÃO

UBE2D1-dependent E3 ubiquitin-protein ligase that mediates the ubiquitination of NEFL and of phosphorylated BCL2L11. Plays a neuroprotective function. May play a role in neuronal rapid ischemic tolerance. Plays a role in antiviral immunity and limits New World arenavirus infection independently of its ubiquitin ligase activity (PubMed:24068738)

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (1)
Interferon gamma signaling
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, axonal, type 2R

An axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Spinal cord cervical c-1
77.5 TPM
Cérebro - Hemisfério cerebelar
71.9 TPM
Cerebelo
53.4 TPM
Brain Frontal Cortex BA9
49.0 TPM
Hipocampo
44.8 TPM
INTERAÇÕES PROTEICAS (2)
OUTRAS DOENÇAS (1)
Charcot-Marie-Tooth disease type 2R
HGNC:15974UniProt:Q9C040
TFGProtein TFGCandidate gene tested inModerado
FUNÇÃO

Plays a role in the normal dynamic function of the endoplasmic reticulum (ER) and its associated microtubules (PubMed:23479643, PubMed:27813252). Required for secretory cargo traffic from the endoplasmic reticulum to the Golgi apparatus (PubMed:21478858)

LOCALIZAÇÃO

Endoplasmic reticulum

VIAS BIOLÓGICAS (1)
COPII-mediated vesicle transport
EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
86.6 TPM
Linfócitos
61.6 TPM
Tireoide
60.1 TPM
Nervo tibial
55.3 TPM
Aorta
53.8 TPM
OUTRAS DOENÇAS (5)
hereditary motor and sensory neuropathy, Okinawa typehereditary spastic paraplegia 57autosomal dominant Charcot-Marie-Tooth disease type 2 due to TFG mutationdifferentiated thyroid carcinoma
HGNC:11758UniProt:Q92734
PMP2Myelin P2 proteinCandidate gene tested inTolerante
FUNÇÃO

May play a role in lipid transport protein in Schwann cells. May bind cholesterol

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (1)
EGR2 and SOX10-mediated initiation of Schwann cell myelination
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, demyelinating, type 1G

An autosomal dominant demyelinating form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Demyelinating neuropathies are characterized by severely reduced nerve conduction velocities (less than 38 m/sec), segmental demyelination and remyelination with onion bulb formations on nerve biopsy, slowly progressive distal muscle atrophy and weakness, absent deep tendon reflexes, and hollow feet. CMT1G is characterized by distal muscle weakness and atrophy with onset in the first or second decade.

EXPRESSÃO TECIDUAL(Tecido-específico)
Brain Spinal cord cervical c-1
501.7 TPM
Nervo tibial
382.4 TPM
Substância negra
272.8 TPM
Hipotálamo
187.1 TPM
Cérebro - Amígdala
186.6 TPM
OUTRAS DOENÇAS (1)
Charcot-Marie-Tooth disease, demyelinating, type 1G
HGNC:9117UniProt:P02689
MORC2ATPase MORC2Candidate gene tested inAltamente restrito
FUNÇÃO

ATP-dependent chromatin remodeler essential for epigenetic silencing by the HUSH (human silencing hub) complex (PubMed:28581500, PubMed:29440755, PubMed:32693025). Recruited by HUSH to target site in heterochromatin, the ATPase activity and homodimerization are critical for HUSH-mediated silencing (PubMed:28581500, PubMed:29440755, PubMed:32693025). Represses germ cell-related genes and L1 retrotransposons in collaboration with SETDB1 and the HUSH complex, the silencing is dependent of repressiv

LOCALIZAÇÃO

NucleusCytoplasm, cytosolChromosomeNucleus matrix

VIAS BIOLÓGICAS (1)
Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, axonal, type 2Z

An autosomal dominant, axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
68.4 TPM
Artéria tibial
33.4 TPM
Útero
33.0 TPM
Cervix Endocervix
32.6 TPM
Cervix Ectocervix
32.2 TPM
INTERAÇÕES PROTEICAS (4)
OUTRAS DOENÇAS (2)
developmental delay, impaired growth, dysmorphic facies, and axonal neuropathyCharcot-Marie-Tooth disease axonal type 2Z
HGNC:23573UniProt:Q9Y6X9
SPG11SpatacsinCandidate gene tested inTolerante
FUNÇÃO

May play a role in neurite plasticity by maintaining cytoskeleton stability and regulating synaptic vesicle transport

LOCALIZAÇÃO

Cytoplasm, cytosolNucleusCell projection, axonCell projection, dendrite

MECANISMO DE DOENÇA

Spastic paraplegia 11, autosomal recessive

A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
33.0 TPM
Tireoide
29.3 TPM
Baço
26.6 TPM
Fibroblastos
23.3 TPM
Pulmão
22.7 TPM
OUTRAS DOENÇAS (4)
amyotrophic lateral sclerosis type 5Charcot-Marie-Tooth disease axonal type 2Xhereditary spastic paraplegia 11juvenile amyotrophic lateral sclerosis
HGNC:11226UniProt:Q96JI7
DNM2Dynamin-2Candidate gene tested inAltamente restrito
FUNÇÃO

Catalyzes the hydrolysis of GTP and utilizes this energy to mediate vesicle scission at plasma membrane during endocytosis and filament remodeling at many actin structures during organization of the actin cytoskeleton (PubMed:15731758, PubMed:19605363, PubMed:19623537, PubMed:33713620, PubMed:34744632). Plays an important role in vesicular trafficking processes, namely clathrin-mediated endocytosis (CME), exocytic and clathrin-coated vesicle from the trans-Golgi network, and PDGF stimulated macr

LOCALIZAÇÃO

Cytoplasm, cytoskeletonCytoplasmic vesicle, clathrin-coated vesicleCell projection, uropodiumEndosomeCytoplasm, cytoskeleton, microtubule organizing center, centrosomeCytoplasm, cytoskeleton, microtubule organizing center, centrosome, centrioleRecycling endosomeCell projection, phagocytic cupCytoplasmic vesicle, phagosome membraneCell projection, podosomeCytoplasmCell junctionPostsynaptic densitySynapse, synaptosomeMidbodyMembrane, clathrin-coated pit

VIAS BIOLÓGICAS (1)
NOSTRIN mediated eNOS trafficking
MECANISMO DE DOENÇA

Myopathy, centronuclear, 1

A congenital muscle disorder characterized by progressive muscular weakness and wasting involving mainly limb girdle, trunk, and neck muscles. It may also affect distal muscles. Weakness may be present during childhood or adolescence or may not become evident until the third decade of life. Ptosis is a frequent clinical feature. The most prominent histopathologic features include high frequency of centrally located nuclei in muscle fibers not secondary to regeneration, radial arrangement of sarcoplasmic strands around the central nuclei, and predominance and hypotrophy of type 1 fibers.

EXPRESSÃO TECIDUAL(Ubíquo)
Pulmão
107.7 TPM
Skin Sun Exposed Lower leg
97.2 TPM
Sangue
94.9 TPM
Intestino delgado
92.3 TPM
Baço
85.9 TPM
OUTRAS DOENÇAS (5)
fetal akinesia-cerebral and retinal hemorrhage syndromeautosomal dominant centronuclear myopathyCharcot-Marie-Tooth disease dominant intermediate Bcentronuclear myopathy
HGNC:2974UniProt:P50570
KIF5AKinesin heavy chain isoform 5ACandidate gene tested inAltamente restrito
FUNÇÃO

Microtubule-dependent motor required for slow axonal transport of neurofilament proteins (NFH, NFM and NFL). Can induce formation of neurite-like membrane protrusions in non-neuronal cells in a ZFYVE27-dependent manner. The ZFYVE27-KIF5A complex contributes to the vesicular transport of VAPA, VAPB, SURF4, RAB11A, RAB11B and RTN3 proteins in neurons. Required for anterograde axonal transportation of MAPK8IP3/JIP3 which is essential for MAPK8IP3/JIP3 function in axon elongation

LOCALIZAÇÃO

Cytoplasm, perinuclear regionCytoplasm, cytoskeletonPerikaryon

VIAS BIOLÓGICAS (5)
RHO GTPases activate KTN1KinesinsCOPI-dependent Golgi-to-ER retrograde trafficMHC class II antigen presentationInsulin processing
MECANISMO DE DOENÇA

Spastic paraplegia 10, autosomal dominant

A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body.

EXPRESSÃO TECIDUAL(Ubíquo)
Córtex cerebral
1160.2 TPM
Brain Frontal Cortex BA9
1085.0 TPM
Brain Anterior cingulate cortex BA24
848.9 TPM
Cérebro - Amígdala
620.8 TPM
Brain Caudate basal ganglia
320.3 TPM
OUTRAS DOENÇAS (4)
hereditary spastic paraplegia 10myoclonus, intractable, neonatalautosomal dominant Charcot-Marie-Tooth disease type 2 due to KIF5A mutationamyotrophic lateral sclerosis, susceptibility to, 25
HGNC:6323UniProt:Q12840
HARS1Histidine--tRNA ligase, cytoplasmicCandidate gene tested inTolerante
FUNÇÃO

Catalyzes the ATP-dependent ligation of histidine to the 3'-end of its cognate tRNA, via the formation of an aminoacyl-adenylate intermediate (His-AMP) (PubMed:29235198). Plays a role in axon guidance (PubMed:26072516)

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (1)
Cytosolic tRNA aminoacylation
MECANISMO DE DOENÇA

Usher syndrome 3B

A syndrome characterized by progressive vision and hearing loss during early childhood. Some patients have the so-called 'Charles Bonnet syndrome,' involving decreased visual acuity and vivid visual hallucinations. USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH3 is characterized by postlingual, progressive hearing loss, variable vestibular dysfunction, and onset of retinitis pigmentosa symptoms, including nyctalopia, constriction of the visual fields, and loss of central visual acuity, usually by the second decade of life.

OUTRAS DOENÇAS (3)
Usher syndrome type 3Bautosomal dominant Charcot-Marie-Tooth disease type 2WUsher syndrome type 3
HGNC:4816UniProt:P12081
AARS1Alanine--tRNA ligase, cytoplasmicCandidate gene tested inTolerante
FUNÇÃO

Catalyzes the attachment of alanine to tRNA(Ala) in a two-step reaction: alanine is first activated by ATP to form Ala-AMP and then transferred to the acceptor end of tRNA(Ala) (PubMed:27622773, PubMed:27911835, PubMed:28493438, PubMed:33909043). Also edits incorrectly charged tRNA(Ala) via its editing domain (PubMed:27622773, PubMed:27911835, PubMed:28493438, PubMed:29273753). In presence of high levels of lactate, also acts as a protein lactyltransferase that mediates lactylation of lysine res

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (1)
Cytosolic tRNA aminoacylation
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, axonal, type 2N

An axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy.

OUTRAS DOENÇAS (6)
trichothiodystrophy 8, nonphotosensitiveleukoencephalopathy, hereditary diffuse, with spheroids 2developmental and epileptic encephalopathy, 29Charcot-Marie-Tooth disease axonal type 2N
HGNC:20UniProt:P49588
PNKPBifunctional polynucleotide phosphatase/kinaseCandidate gene tested inTolerante
FUNÇÃO

Plays a key role in the repair of DNA damage, functioning as part of both the non-homologous end-joining (NHEJ) and base excision repair (BER) pathways (PubMed:10446192, PubMed:10446193, PubMed:15385968, PubMed:20852255, PubMed:28453785). Through its two catalytic activities, PNK ensures that DNA termini are compatible with extension and ligation by either removing 3'-phosphates from, or by phosphorylating 5'-hydroxyl groups on, the ribose sugar of the DNA backbone (PubMed:10446192, PubMed:10446

LOCALIZAÇÃO

NucleusChromosome

VIAS BIOLÓGICAS (1)
APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway
MECANISMO DE DOENÇA

Microcephaly, seizures, and developmental delay

An autosomal recessive neurodevelopmental disorder characterized by infantile-onset seizures, microcephaly, severe intellectual disability and delayed motor milestones with absent speech or only achieving a few words. Most patients also have behavioral problems with hyperactivity. Microcephaly is progressive and without neuronal migration or structural abnormalities, consistent with primary microcephaly.

EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
66.8 TPM
Tireoide
63.9 TPM
Baço
59.2 TPM
Glândula adrenal
55.9 TPM
Cervix Endocervix
51.8 TPM
OUTRAS DOENÇAS (4)
microcephaly, seizures, and developmental delayataxia - oculomotor apraxia type 4Charcot-Marie-Tooth disease type 2B2early-infantile DEE
HGNC:9154UniProt:Q96T60
DGAT2Diacylglycerol O-acyltransferase 2Candidate gene tested inTolerante
FUNÇÃO

Essential acyltransferase that catalyzes the terminal and only committed step in triacylglycerol synthesis by using diacylglycerol and fatty acyl CoA as substrates. Required for synthesis and storage of intracellular triglycerides (PubMed:27184406). Probably plays a central role in cytosolic lipid accumulation. In liver, is primarily responsible for incorporating endogenously synthesized fatty acids into triglycerides (By similarity). Also functions as an acyl-CoA retinol acyltransferase (ARAT)

LOCALIZAÇÃO

Endoplasmic reticulum membraneLipid dropletCytoplasm, perinuclear region

VIAS BIOLÓGICAS (3)
Acyl chain remodeling of DAG and TAGMLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosisTriglyceride biosynthesis
EXPRESSÃO TECIDUAL(Ubíquo)
Skin Sun Exposed Lower leg
195.8 TPM
Skin Not Sun Exposed Suprapubic
161.5 TPM
Adipose Visceral Omentum
126.7 TPM
Sangue
111.6 TPM
Tecido adiposo
108.9 TPM
OUTRAS DOENÇAS (1)
autosomal dominant charcot-marie-tooth disease type 2 due to DGAT2 mutation
HGNC:16940UniProt:Q96PD7
ITPR3Inositol 1,4,5-trisphosphate-gated calcium channel ITPR3Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Inositol 1,4,5-trisphosphate-gated calcium channel that, upon 1D-myo-inositol 1,4,5-trisphosphate binding, transports calcium from the endoplasmic reticulum lumen to cytoplasm, thus releasing the intracellular calcium and therefore participates in cellular calcium ion homeostasis (PubMed:32949214, PubMed:37898605, PubMed:8081734, PubMed:8288584, PubMed:39560673). 1D-myo-inositol 1,4,5-trisphosphate binds to the ligand-free channel without altering its global conformation, yielding the low-energy

LOCALIZAÇÃO

Endoplasmic reticulum membraneCytoplasmic vesicle, secretory vesicle membrane

VIAS BIOLÓGICAS (10)
Ion homeostasisRegulation of insulin secretionFCGR3A-mediated IL10 synthesisAntigen activates B Cell Receptor (BCR) leading to generation of second messengersCLEC7A (Dectin-1) induces NFAT activation
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, demyelinating, type 1J

An autosomal dominant demyelinating form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Demyelinating neuropathies are characterized by severely reduced nerve conduction velocities (less than 38 m/sec), segmental demyelination and remyelination with onion bulb formations on nerve biopsy, slowly progressive distal muscle atrophy and weakness, absent deep tendon reflexes, and hollow feet.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
135.8 TPM
Tireoide
133.3 TPM
Skin Not Sun Exposed Suprapubic
107.1 TPM
Skin Sun Exposed Lower leg
105.5 TPM
Baço
74.9 TPM
OUTRAS DOENÇAS (1)
Charcot-Marie-Tooth disease, demyelinating, type 1J
HGNC:HGNC:6182UniProt:Q14573
POLR3BDNA-directed RNA polymerase III subunit RPC2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalytic core component of RNA polymerase III (Pol III), a DNA-dependent RNA polymerase which synthesizes small non-coding RNAs using the four ribonucleoside triphosphates as substrates. Synthesizes 5S rRNA, snRNAs, tRNAs and miRNAs from at least 500 distinct genomic loci (PubMed:20413673, PubMed:33558766). Pol III-mediated transcription cycle proceeds through transcription initiation, transcription elongation and transcription termination stages. During transcription initiation, Pol III is rec

LOCALIZAÇÃO

NucleusCytoplasm, cytosol

VIAS BIOLÓGICAS (1)
Cytosolic sensors of pathogen-associated DNA
MECANISMO DE DOENÇA

Leukodystrophy, hypomyelinating, 8, with or without oligodontia and/or hypogonadotropic hypogonadism

An autosomal recessive neurodegenerative disorder characterized by early childhood onset of cerebellar ataxia and mild intellectual disabilities associated with diffuse hypomyelination apparent on brain MRI. Variable features include oligodontia and/or hypogonadotropic hypogonadism.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
10.8 TPM
Skin Sun Exposed Lower leg
9.5 TPM
Esôfago - Mucosa
8.9 TPM
Skin Not Sun Exposed Suprapubic
8.5 TPM
Vagina
8.0 TPM
OUTRAS DOENÇAS (3)
hypomyelinating leukodystrophy 8 with or without oligodontia and-or hypogonadotropic hypogonadismCharcot-Marie-Tooth disease, demyelinating, IIA 1Iobsolete hypomyelination-hypogonadotropic hypogonadism-hypodontia syndrome
HGNC:30348UniProt:Q9NW08
TRPV4Transient receptor potential cation channel subfamily V member 4Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Non-selective calcium permeant cation channel involved in osmotic sensitivity and mechanosensitivity (PubMed:16293632, PubMed:18695040, PubMed:18826956, PubMed:22526352, PubMed:23136043, PubMed:29899501). Activation by exposure to hypotonicity within the physiological range exhibits an outward rectification (PubMed:18695040, PubMed:18826956, PubMed:29899501). Also activated by heat, low pH, citrate and phorbol esters (PubMed:16293632, PubMed:18695040, PubMed:18826956, PubMed:20037586, PubMed:219

LOCALIZAÇÃO

Cell membraneApical cell membraneCell junction, adherens junctionCell projection, ciliumEndoplasmic reticulum

VIAS BIOLÓGICAS (2)
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cellsTRP channels
MECANISMO DE DOENÇA

Brachyolmia 3

A form of brachyolmia, a clinically and genetically heterogeneous skeletal dysplasia primarily affecting the spine and characterized by a short trunk, short stature, and platyspondyly. BCYM3 is an autosomal dominant form with severe scoliosis with or without kyphosis, and flattened irregular cervical vertebrae.

EXPRESSÃO TECIDUAL(Tecido-específico)
Glândula salivar
28.0 TPM
Esôfago - Mucosa
13.4 TPM
Rim - Córtex
13.3 TPM
Próstata
12.8 TPM
Skin Sun Exposed Lower leg
12.0 TPM
OUTRAS DOENÇAS (11)
spondyloepimetaphyseal dysplasia, Maroteaux typeneuronopathy, distal hereditary motor, autosomal dominant 8scapuloperoneal spinal muscular atrophy, autosomal dominantfamilial digital arthropathy-brachydactyly
HGNC:18083UniProt:Q9HBA0
SURF1Surfeit locus protein 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Component of the MITRAC (mitochondrial translation regulation assembly intermediate of cytochrome c oxidase complex) complex, that regulates cytochrome c oxidase assembly

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (1)
Complex IV assembly
MECANISMO DE DOENÇA

Mitochondrial complex IV deficiency, nuclear type 1

An autosomal recessive disorder of the mitochondrial respiratory chain characterized by early-onset, rapidly progressive encephalopathy, neurodegeneration, and loss of motor and cognitive skills. Affected individuals show hypotonia, failure to thrive, loss of the ability to sit or walk, poor communication, poor eye contact, oculomotor abnormalities, as well as deafness, ataxia, tremor, and brisk tendon reflexes. Brain imaging shows bilateral symmetric lesions in the basal ganglia. Lactate levels in serum and cerebrospinal fluid are increased. Patient tissues show decreased levels and activity of mitochondrial respiratory complex IV. Death in childhood may occur, often due to central respiratory failure.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
67.2 TPM
Artéria tibial
65.0 TPM
Aorta
63.9 TPM
Cólon sigmoide
62.4 TPM
Esôfago - Junção
60.0 TPM
OUTRAS DOENÇAS (2)
mitochondrial complex IV deficiency, nuclear type 1Charcot-Marie-Tooth disease type 4K
HGNC:11474UniProt:Q15526
LMNAPrelamin-A/CDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Lamins are intermediate filament proteins that assemble into a filamentous meshwork, and which constitute the major components of the nuclear lamina, a fibrous layer on the nucleoplasmic side of the inner nuclear membrane (PubMed:10080180, PubMed:10580070, PubMed:10587585, PubMed:10814726, PubMed:11799477, PubMed:12075506, PubMed:12927431, PubMed:15317753, PubMed:18551513, PubMed:18611980, PubMed:2188730, PubMed:22431096, PubMed:2344612, PubMed:23666920, PubMed:24741066, PubMed:31434876, PubMed:

LOCALIZAÇÃO

Nucleus laminaNucleus envelopeNucleus, nucleoplasmNucleus matrixNucleus speckle

VIAS BIOLÓGICAS (1)
Initiation of Nuclear Envelope (NE) Reformation
MECANISMO DE DOENÇA

Emery-Dreifuss muscular dystrophy 2, autosomal dominant

A form of Emery-Dreifuss muscular dystrophy, a degenerative myopathy characterized by weakness and atrophy of muscle without involvement of the nervous system, early contractures of the elbows, Achilles tendons and spine, and cardiomyopathy associated with cardiac conduction defects.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
392.7 TPM
Aorta
300.6 TPM
Skin Not Sun Exposed Suprapubic
297.7 TPM
Skin Sun Exposed Lower leg
272.6 TPM
Útero
255.8 TPM
OUTRAS DOENÇAS (23)
restrictive dermopathy 2familial partial lipodystrophy, Dunnigan typedilated cardiomyopathy-hypergonadotropic hypogonadism syndromemandibuloacral dysplasia with type A lipodystrophy
HGNC:6636UniProt:P02545
MPV17Mitochondrial inner membrane protein Mpv17Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Non-selective channel that modulates the membrane potential under normal conditions and oxidative stress, and is involved in mitochondrial homeostasis (PubMed:25861990). Involved in mitochondrial deoxynucleoside triphosphates (dNTP) pool homeostasis and mitochondrial DNA (mtDNA) maintenance (PubMed:26760297). May be involved in the regulation of reactive oxygen species metabolism and the control of oxidative phosphorylation (By similarity)

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (1)
Peroxisomal protein import
MECANISMO DE DOENÇA

Mitochondrial DNA depletion syndrome 6

A disease due to mitochondrial dysfunction. It is characterized by infantile onset of progressive liver failure, often leading to death in the first year of life, peripheral neuropathy, corneal scarring, acral ulceration and osteomyelitis leading to autoamputation, cerebral leukoencephalopathy, failure to thrive, and recurrent metabolic acidosis with intercurrent infections.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
57.1 TPM
Glândula adrenal
48.8 TPM
Tireoide
40.6 TPM
Linfócitos
39.3 TPM
Pituitária
36.5 TPM
OUTRAS DOENÇAS (2)
mitochondrial DNA depletion syndrome 6 (hepatocerebral type)Charcot-Marie-Tooth disease, axonal, type 2EE
HGNC:7224UniProt:P39210
MTMR2Phosphatidylinositol-3,5-bisphosphate 3-phosphatase MTMR2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Lipid phosphatase that specifically dephosphorylates the D-3 position of phosphatidylinositol 3-phosphate and phosphatidylinositol 3,5-bisphosphate, generating phosphatidylinositol and phosphatidylinositol 5-phosphate (PubMed:11733541, PubMed:12668758, PubMed:14690594, PubMed:21372139). Regulates the level of these phosphoinositides critical for various biological processes including autophagy initiation and autophagosome maturation (PubMed:35580604)

LOCALIZAÇÃO

CytoplasmEarly endosome membraneCytoplasm, perinuclear regionCell projection, axonEndosome membrane

VIAS BIOLÓGICAS (4)
Synthesis of PIPs at the early endosome membraneSynthesis of PIPs at the late endosome membraneSynthesis of PIPs at the ER membraneSynthesis of PIPs at the plasma membrane
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, demyelinating, type 4B1

A recessive demyelinating form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Demyelinating neuropathies are characterized by severely reduced nerve conduction velocities (less than 38 m/sec), segmental demyelination and remyelination with onion bulb formations on nerve biopsy, slowly progressive distal muscle atrophy and weakness, absent deep tendon reflexes, and hollow feet. By convention autosomal recessive forms of demyelinating Charcot-Marie-Tooth disease are designated CMT4.

EXPRESSÃO TECIDUAL(Ubíquo)
Artéria tibial
27.3 TPM
Aorta
26.0 TPM
Artéria coronária
25.6 TPM
Testículo
25.4 TPM
Brain Spinal cord cervical c-1
24.0 TPM
OUTRAS DOENÇAS (1)
Charcot-Marie-Tooth disease type 4B1
HGNC:7450UniProt:Q13614
KIF1BKinesin-like protein KIF1BDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Has a plus-end-directed microtubule motor activity and functions as a motor for transport of vesicles and organelles along microtubules Has a plus-end-directed microtubule motor activity and functions as a motor for anterograde synaptic vesicle transport along axonal microtubules from the cell body to the presynapse in neuronal cells (By similarity). Functions as a downstream effector in a developmental apoptotic pathway that is activated when nerve growth factor (NGF) becomes limiting for neuro

LOCALIZAÇÃO

Cytoplasm, cytoskeletonCytoplasmic vesicle, secretory vesicle, synaptic vesicle membraneMitochondrion

VIAS BIOLÓGICAS (2)
KinesinsCOPI-dependent Golgi-to-ER retrograde traffic
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, axonal, type 2A1

A dominant axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
105.8 TPM
Cerebelo
84.6 TPM
Músculo esquelético
61.1 TPM
Brain Frontal Cortex BA9
56.3 TPM
Córtex cerebral
53.1 TPM
OUTRAS DOENÇAS (3)
Charcot-Marie-Tooth disease type 2A1hereditary pheochromocytoma-paragangliomaneuroblastoma, susceptibility to, 1
HGNC:16636UniProt:O60333
COX6A1Cytochrome c oxidase subunit 6A1, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Component of the cytochrome c oxidase, the last enzyme in the mitochondrial electron transport chain which drives oxidative phosphorylation. The respiratory chain contains 3 multisubunit complexes succinate dehydrogenase (complex II, CII), ubiquinol-cytochrome c oxidoreductase (cytochrome b-c1 complex, complex III, CIII) and cytochrome c oxidase (complex IV, CIV), that cooperate to transfer electrons derived from NADH and succinate to molecular oxygen, creating an electrochemical gradient over t

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (4)
Cytoprotection by HMOX1Respiratory electron transportTP53 Regulates Metabolic GenesComplex IV assembly
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, recessive intermediate D

A form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Recessive intermediate forms of Charcot-Marie-Tooth disease are characterized by clinical and pathologic features intermediate between demyelinating and axonal peripheral neuropathies, and motor median nerve conduction velocities ranging from 25 to 45 m/sec.

OUTRAS DOENÇAS (1)
Charcot-Marie-Tooth disease recessive intermediate D
HGNC:2277UniProt:P12074
FBLN5Fibulin-5Disease-causing germline mutation(s) inRestrito
FUNÇÃO

Essential for elastic fiber formation, is involved in the assembly of continuous elastin (ELN) polymer and promotes the interaction of microfibrils and ELN (PubMed:18185537). Stabilizes and organizes elastic fibers in the skin, lung and vasculature (By similarity). Promotes adhesion of endothelial cells through interaction of integrins and the RGD motif. Vascular ligand for integrin receptors which may play a role in vascular development and remodeling (PubMed:10428823). May act as an adapter th

LOCALIZAÇÃO

SecretedSecreted, extracellular space, extracellular matrix

VIAS BIOLÓGICAS (2)
Molecules associated with elastic fibresElastic fibre formation
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, demyelinating, type 1H

An autosomal dominant demyelinating form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Demyelinating neuropathies are characterized by severely reduced nerve conduction velocities (less than 38 m/sec), segmental demyelination and remyelination with onion bulb formations on nerve biopsy, slowly progressive distal muscle atrophy and weakness, absent deep tendon reflexes, and hollow feet. CMT1H is characterized by peripheral sensorimotor neuropathy with onset usually in adulthood. Affected individuals present with foot deformities, upper or lower limb sensory disturbances, and motor deficits, mainly impaired gait. Rare patients may have hyperelastic skin or develop age-related macular degeneration.

EXPRESSÃO TECIDUAL(Ubíquo)
Aorta
795.1 TPM
Fibroblastos
292.3 TPM
Artéria coronária
255.6 TPM
Útero
195.1 TPM
Artéria tibial
192.2 TPM
OUTRAS DOENÇAS (7)
macular degeneration, age-related, 3cutis laxa, autosomal recessive, type 1Acutis laxa, autosomal dominant 2Charcot-Marie-Tooth disease, demyelinating, IIA 1H
HGNC:3602UniProt:Q9UBX5
GBF1Golgi-specific brefeldin A-resistance guanine nucleotide exchange factor 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Guanine-nucleotide exchange factor (GEF) for members of the Arf family of small GTPases involved in trafficking in the early secretory pathway; its GEF activity initiates the coating of nascent vesicles via the localized generation of activated ARFs through replacement of GDP with GTP. Recruitment to cis-Golgi membranes requires membrane association of Arf-GDP and can be regulated by ARF1, ARF3, ARF4 and ARF5. Involved in the recruitment of the COPI coat complex to the endoplasmic reticulum exit

LOCALIZAÇÃO

Golgi apparatus, cis-Golgi networkEndoplasmic reticulum-Golgi intermediate compartmentGolgi apparatus, trans-Golgi networkGolgi apparatusCytoplasmLipid dropletMembrane

VIAS BIOLÓGICAS (3)
COPI-mediated anterograde transportDengue Virus-Host InteractionsCOPI-dependent Golgi-to-ER retrograde traffic
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, axonal, type 2GG

An axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy. CMT2GG is an autosomal dominant form characterized by slowly progressive distal muscle weakness and atrophy primarily affecting the lower limbs and causing difficulty walking. Some individuals may also have involvement of the hands.

EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
70.4 TPM
Cerebelo
66.7 TPM
Tireoide
66.5 TPM
Útero
60.7 TPM
Cervix Endocervix
58.4 TPM
OUTRAS DOENÇAS (1)
Charcot-Marie-Tooth Disease, axonal, type 2GG
HGNC:HGNC:4181UniProt:Q92538
DHTKD12-oxoadipate dehydrogenase complex component E1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

2-oxoadipate dehydrogenase (E1a) component of the 2-oxoadipate dehydrogenase complex (OADHC) (PubMed:29191460, PubMed:29752936, PubMed:32303640, PubMed:32633484, PubMed:32695416). Participates in the first step, rate limiting for the overall conversion of 2-oxoadipate (alpha-ketoadipate) to glutaryl-CoA and CO(2) catalyzed by the whole OADHC (PubMed:29191460, PubMed:32695416). Catalyzes the irreversible decarboxylation of 2-oxoadipate via the thiamine diphosphate (ThDP) cofactor and subsequent t

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (1)
OADH complex synthesizes glutaryl-CoA from 2-OA
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, axonal, type 2Q

An axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy.

EXPRESSÃO TECIDUAL(Ubíquo)
Fígado
51.2 TPM
Linfócitos
43.7 TPM
Ovário
22.0 TPM
Nervo tibial
17.9 TPM
Tireoide
17.1 TPM
OUTRAS DOENÇAS (2)
Charcot-Marie-Tooth disease axonal type 2Q2-aminoadipic 2-oxoadipic aciduria
HGNC:23537UniProt:Q96HY7
ATP1A1Sodium/potassium-transporting ATPase subunit alpha-1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates the electrochemical gradient of sodium and potassium ions, providing the energy for active transport of various nutrients (PubMed:29499166, PubMed:30388404). Could also be part of an osmosensory signaling pathway that senses body-fluid sodium levels and controls salt intake behavior as well as voluntary

LOCALIZAÇÃO

Cell membraneBasolateral cell membraneCell membrane, sarcolemmaCell projection, axonMelanosome

VIAS BIOLÓGICAS (3)
Ion homeostasisIon transport by P-type ATPasesPotential therapeutics for SARS
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, axonal, type 2DD

A dominant axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy.

OUTRAS DOENÇAS (2)
Charcot-Marie-tooth disease, axonal, type 2DDhypomagnesemia, seizures, and intellectual disability 2
HGNC:799UniProt:P05023
HSPB8Heat shock protein beta-8Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Involved in the chaperone-assisted selective autophagy (CASA), a crucial process for protein quality control, particularly in mechanical strained cells and tissues such as muscle. Displays temperature-dependent chaperone activity

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (1)
HSF1-dependent transactivation
MECANISMO DE DOENÇA

Neuronopathy, distal hereditary motor, autosomal dominant 2

A form of distal hereditary motor neuronopathy, a heterogeneous group of neuromuscular disorders caused by selective degeneration of motor neurons in the anterior horn of the spinal cord, without sensory deficit in the posterior horn. The overall clinical picture consists of a classical distal muscular atrophy syndrome in the legs without clinical sensory loss. The disease starts with weakness and wasting of distal muscles of the anterior tibial and peroneal compartments of the legs. Later on, weakness and atrophy may expand to the proximal muscles of the lower limbs and/or to the distal upper limbs.

EXPRESSÃO TECIDUAL(Ubíquo)
Esôfago - Muscular
583.2 TPM
Cólon sigmoide
522.6 TPM
Músculo esquelético
501.7 TPM
Esôfago - Junção
499.1 TPM
Artéria tibial
307.4 TPM
OUTRAS DOENÇAS (4)
myopathy, myofibrillar, 13, with rimmed vacuolesneuronopathy, distal hereditary motor, type 2ACharcot-Marie-Tooth disease axonal type 2Ldistal hereditary motor neuropathy type 2
HGNC:30171UniProt:Q9UJY1
JAG1Protein jagged-1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Ligand for multiple Notch receptors and involved in the mediation of Notch signaling (PubMed:18660822, PubMed:20437614). May be involved in cell-fate decisions during hematopoiesis (PubMed:9462510). Seems to be involved in early and late stages of mammalian cardiovascular development. Inhibits myoblast differentiation (By similarity). Enhances fibroblast growth factor-induced angiogenesis (in vitro)

LOCALIZAÇÃO

MembraneCell membrane

VIAS BIOLÓGICAS (10)
NOTCH2 Activation and Transmission of Signal to the NucleusRAC3 GTPase cycleRAC1 GTPase cycleActivated NOTCH1 Transmits Signal to the NucleusConstitutive Signaling by NOTCH1 PEST Domain Mutants
MECANISMO DE DOENÇA

Alagille syndrome 1

A form of Alagille syndrome, an autosomal dominant multisystem disorder. It is clinically defined by hepatic bile duct paucity and cholestasis in association with cardiac, skeletal, and ophthalmologic manifestations. There are characteristic facial features and less frequent clinical involvement of the renal and vascular systems.

EXPRESSÃO TECIDUAL(Ubíquo)
Artéria tibial
202.9 TPM
Artéria coronária
150.2 TPM
Aorta
133.4 TPM
Skin Sun Exposed Lower leg
102.3 TPM
Vagina
102.2 TPM
OUTRAS DOENÇAS (5)
tetralogy of fallotCharcot-Marie-Tooth disease, axonal, Type 2HHAlagille syndrome due to a JAG1 point mutationdeafness, congenital heart defects, and posterior embryotoxon
HGNC:6188UniProt:P78504
MFN2Mitofusin-2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Mitochondrial outer membrane GTPase that mediates mitochondrial clustering and fusion (PubMed:11181170, PubMed:11950885, PubMed:19889647, PubMed:26214738, PubMed:28114303). Mitochondria are highly dynamic organelles, and their morphology is determined by the equilibrium between mitochondrial fusion and fission events (PubMed:28114303). Overexpression induces the formation of mitochondrial networks (PubMed:28114303). Membrane clustering requires GTPase activity and may involve a major rearrangeme

LOCALIZAÇÃO

Mitochondrion outer membrane

VIAS BIOLÓGICAS (2)
Factors involved in megakaryocyte development and platelet productionRHOT2 GTPase cycle
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, axonal, type 2A2B

An axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy. CMT2A2B is a severe form with autosomal recessive inheritance.

EXPRESSÃO TECIDUAL(Ubíquo)
Coração - Ventrículo esquerdo
173.4 TPM
Músculo esquelético
158.4 TPM
Esôfago - Muscular
143.1 TPM
Coração - Átrio
137.5 TPM
Esôfago - Junção
119.7 TPM
OUTRAS DOENÇAS (7)
multiple symmetric lipomatosisCharcot-Marie-Tooth disease type 2A2Charcot-Marie-Tooth disease, axonal, autosomal recessive, type 2a2b;neuropathy, hereditary motor and sensory, type 6A
HGNC:16877UniProt:O95140
DCAF8DDB1- and CUL4-associated factor 8Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

May function as a substrate receptor for CUL4-DDB1 E3 ubiquitin-protein ligase complex

LOCALIZAÇÃO

NucleusCytoplasm

VIAS BIOLÓGICAS (1)
Neddylation
MECANISMO DE DOENÇA

Giant axonal neuropathy 2, autosomal dominant

An autosomal dominant peripheral axonal neuropathy characterized by onset of distal sensory impairment with lower extremity muscle weakness and atrophy after the second decade. Clinical features include foot deformities apparent in childhood, and cardiomyopathy in severely affected individuals. Sural nerve biopsy shows giant axonal swelling with neurofilament accumulation.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
121.7 TPM
Nervo tibial
116.4 TPM
Cerebelo
116.0 TPM
Cérebro - Hemisfério cerebelar
112.3 TPM
Útero
97.2 TPM
OUTRAS DOENÇAS (1)
giant axonal neuropathy 2
HGNC:24891UniProt:Q5TAQ9
FGD4FYVE, RhoGEF and PH domain-containing protein 4Disease-causing germline mutation(s) inRestrito
FUNÇÃO

Activates CDC42, a member of the Ras-like family of Rho- and Rac proteins, by exchanging bound GDP for free GTP. Plays a role in regulating the actin cytoskeleton and cell shape. Activates MAPK8 (By similarity)

LOCALIZAÇÃO

Cytoplasm, cytoskeletonCell projection, filopodium

VIAS BIOLÓGICAS (3)
G alpha (12/13) signalling eventsNRAGE signals death through JNKCDC42 GTPase cycle
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, demyelinating, type 4H

A recessive demyelinating form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Demyelinating neuropathies are characterized by severely reduced nerve conduction velocities (less than 38 m/sec), segmental demyelination and remyelination with onion bulb formations on nerve biopsy, slowly progressive distal muscle atrophy and weakness, absent deep tendon reflexes, and hollow feet. By convention autosomal recessive forms of demyelinating Charcot-Marie-Tooth disease are designated CMT4.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
21.7 TPM
Ovário
21.7 TPM
Nervo tibial
18.9 TPM
Tecido adiposo
16.5 TPM
Estômago
14.5 TPM
INTERAÇÕES PROTEICAS (4)
OUTRAS DOENÇAS (1)
Charcot-Marie-Tooth disease type 4H
HGNC:19125UniProt:Q96M96
PRXPeriaxinDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Scaffolding protein that functions as part of a dystroglycan complex in Schwann cells, and as part of EZR and AHNAK-containing complexes in eye lens fiber cells. Required for the maintenance of the peripheral myelin sheath that is essential for normal transmission of nerve impulses and normal perception of sensory stimuli. Required for normal transport of MBP mRNA from the perinuclear to the paranodal regions. Required for normal remyelination after nerve injury. Required for normal elongation o

LOCALIZAÇÃO

Cell membraneNucleusCytoplasmCell junction

VIAS BIOLÓGICAS (1)
EGR2 and SOX10-mediated initiation of Schwann cell myelination
MECANISMO DE DOENÇA

Dejerine-Sottas syndrome

A severe degenerating neuropathy of the demyelinating Charcot-Marie-Tooth disease category, with onset by age 2 years. Characterized by motor and sensory neuropathy with very slow nerve conduction velocities, increased cerebrospinal fluid protein concentrations, hypertrophic nerve changes, delayed age of walking as well as areflexia. There are both autosomal dominant and autosomal recessive forms of Dejerine-Sottas syndrome.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
707.6 TPM
Pulmão
61.5 TPM
Tireoide
19.0 TPM
Cervix Endocervix
11.2 TPM
Útero
10.6 TPM
OUTRAS DOENÇAS (2)
Charcot-Marie-Tooth disease type 4FCharcot-Marie-Tooth disease type 3
HGNC:13797UniProt:Q9BXM0
PLEKHG5Pleckstrin homology domain-containing family G member 5Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Functions as a guanine exchange factor (GEF) for RAB26 and thus regulates autophagy of synaptic vesicles in axon terminal of motoneurons (By similarity). Involved in the control of neuronal cell differentiation (PubMed:11704860). Plays a role in angiogenesis through regulation of endothelial cells chemotaxis. Also affects the migration, adhesion, and matrix/bone degradation in macrophages and osteoclasts (PubMed:23777631)

LOCALIZAÇÃO

CytoplasmCytoplasm, perinuclear regionCell membraneCell junctionCell projection, lamellipodium

VIAS BIOLÓGICAS (5)
G alpha (12/13) signalling eventsNRAGE signals death through JNKRND1 GTPase cycleRND3 GTPase cycleRHOA GTPase cycle
MECANISMO DE DOENÇA

Neuronopathy, distal hereditary motor, autosomal recessive 4

A form of distal hereditary motor neuronopathy, a heterogeneous group of neuromuscular disorders caused by selective degeneration of motor neurons in the anterior horn of the spinal cord, without sensory deficit in the posterior horn. The overall clinical picture consists of a classical distal muscular atrophy syndrome in the legs without clinical sensory loss. The disease starts with weakness and wasting of distal muscles of the anterior tibial and peroneal compartments of the legs. Later on, weakness and atrophy may expand to the proximal muscles of the lower limbs and/or to the distal upper limbs. HMNR4 is characterized by childhood onset, generalized muscle weakness and atrophy with denervation and normal sensation. Bulbar symptoms and pyramidal signs are absent.

EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
244.8 TPM
Cérebro - Hemisfério cerebelar
198.3 TPM
Skin Not Sun Exposed Suprapubic
118.5 TPM
Skin Sun Exposed Lower leg
101.4 TPM
Baço
78.8 TPM
INTERAÇÕES PROTEICAS (3)
OUTRAS DOENÇAS (2)
Charcot-Marie-Tooth disease recessive intermediate Cneuronopathy, distal hereditary motor, autosomal recessive 4
HGNC:29105UniProt:O94827
MARS1Methionine--tRNA ligase, cytoplasmicDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the specific attachment of an amino acid to its cognate tRNA in a 2 step reaction: the amino acid (AA) is first activated by ATP to form AA-AMP and then transferred to the acceptor end of the tRNA (PubMed:11714285). Plays a role in the synthesis of ribosomal RNA in the nucleolus (PubMed:10791971)

LOCALIZAÇÃO

Cytoplasm, cytosolNucleus, nucleolus

VIAS BIOLÓGICAS (3)
Selenoamino acid metabolismCytosolic tRNA aminoacylationTranscriptional and post-translational regulation of MITF-M expression and activity
MECANISMO DE DOENÇA

Interstitial lung and liver disease

An autosomal recessive, life-threatening disorder characterized by respiratory insufficiency and progressive liver disease with onset in infancy or early childhood. Clinical features include failure to thrive, hypotonia, intermittent lactic acidosis, aminoaciduria, hypothyroidism, interstitial lung disease, pulmonary alveolar proteinosis, anemia, and liver canalicular cholestasis, steatosis, and iron deposition.

OUTRAS DOENÇAS (4)
severe early-onset pulmonary alveolar proteinosis due to MARS deficiencyautosomal recessive spastic paraplegia type 70Charcot-Marie-Tooth disease axonal type 2Utrichothiodystrophy 9, nonphotosensitive
HGNC:6898UniProt:P56192
DYNC1H1Cytoplasmic dynein 1 heavy chain 1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Cytoplasmic dynein 1 acts as a motor for the intracellular retrograde motility of vesicles and organelles along microtubules. Dynein has ATPase activity; the force-producing power stroke is thought to occur on release of ADP. Plays a role in mitotic spindle assembly and metaphase plate congression (PubMed:27462074)

LOCALIZAÇÃO

Cytoplasm, cytoskeleton

VIAS BIOLÓGICAS (10)
AggrephagyAmplification of signal from unattached kinetochores via a MAD2 inhibitory signalRHO GTPases Activate ForminsMitotic PrometaphaseEML4 and NUDC in mitotic spindle formation
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, axonal, type 2O

An axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
147.9 TPM
Cérebro - Hemisfério cerebelar
140.0 TPM
Cerebelo
129.1 TPM
Nervo tibial
80.3 TPM
Artéria tibial
78.4 TPM
OUTRAS DOENÇAS (4)
autosomal dominant childhood-onset proximal spinal muscular atrophy without contracturesCharcot-Marie-Tooth disease axonal type 2Ointellectual disability, autosomal dominant 13autosomal dominant non-syndromic intellectual disability
HGNC:2961UniProt:Q14204
SLC12A6Solute carrier family 12 member 6Disease-causing germline mutation(s) inRestrito
FUNÇÃO

Mediates electroneutral potassium-chloride cotransport when activated by cell swelling (PubMed:10600773, PubMed:11551954, PubMed:16048901, PubMed:18566107, PubMed:19665974, PubMed:21628467, PubMed:27485015). May contribute to cell volume homeostasis in single cells (PubMed:16048901, PubMed:27485015) Mediates electroneutral potassium-chloride cotransport when activated by cell swelling (PubMed:16048901, PubMed:33199848, PubMed:34031912). May contribute to cell volume homeostasis in single cells (

LOCALIZAÇÃO

Cell membraneBasolateral cell membrane

VIAS BIOLÓGICAS (1)
Cation-coupled Chloride cotransporters
MECANISMO DE DOENÇA

Agenesis of the corpus callosum, with peripheral neuropathy

A disease that is characterized by severe progressive sensorimotor neuropathy, intellectual disability, dysmorphic features and complete or partial agenesis of the corpus callosum.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
30.3 TPM
Testículo
30.2 TPM
Vagina
27.9 TPM
Sangue
27.8 TPM
Esôfago - Mucosa
25.5 TPM
INTERAÇÕES PROTEICAS (4)
OUTRAS DOENÇAS (2)
Charcot-Marie-Tooth disease, axonal, IIa 2IIagenesis of the corpus callosum with peripheral neuropathy
HGNC:10914UniProt:Q9UHW9
GDAP1Ganglioside-induced differentiation-associated protein 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Regulates the mitochondrial network by promoting mitochondrial fission

LOCALIZAÇÃO

Mitochondrion outer membraneCytoplasm

VIAS BIOLÓGICAS (1)
Class I peroxisomal membrane protein import
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, demyelinating, type 4A

A recessive demyelinating form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Demyelinating neuropathies are characterized by severely reduced nerve conduction velocities (less than 38 m/sec), segmental demyelination and remyelination with onion bulb formations on nerve biopsy, slowly progressive distal muscle atrophy and weakness, absent deep tendon reflexes, and hollow feet. By convention autosomal recessive forms of demyelinating Charcot-Marie-Tooth disease are designated CMT4. CMT4A is a severe form characterized by early age of onset and rapid progression leading to inability to walk in late childhood or adolescence.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
80.1 TPM
Brain Frontal Cortex BA9
56.7 TPM
Cerebelo
56.0 TPM
Pituitária
40.1 TPM
Brain Anterior cingulate cortex BA24
37.6 TPM
OUTRAS DOENÇAS (6)
Charcot-Marie-Tooth disease type 4ACharcot-Marie-Tooth disease, axonal, with vocal cord paresis, autosomal recessiveCharcot-Marie-Tooth disease recessive intermediate ACharcot-Marie-Tooth disease axonal type 2K
HGNC:15968UniProt:Q8TB36
GARS1Glycine--tRNA ligaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the ATP-dependent ligation of glycine to the 3'-end of its cognate tRNA, via the formation of an aminoacyl-adenylate intermediate (Gly-AMP) (PubMed:17544401, PubMed:24898252, PubMed:28675565). Also produces diadenosine tetraphosphate (Ap4A), a universal pleiotropic signaling molecule needed for cell regulation pathways, by direct condensation of 2 ATPs. Thereby, may play a special role in Ap4A homeostasis (PubMed:19710017)

LOCALIZAÇÃO

CytoplasmCell projection, axonSecretedSecreted, extracellular exosomeMitochondrion

VIAS BIOLÓGICAS (1)
Cytosolic tRNA aminoacylation
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, axonal, type 2D

A dominant axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy.

OUTRAS DOENÇAS (4)
neuronopathy, distal hereditary motor, type 5ACharcot-Marie-Tooth disease type 2Dspinal muscular atrophy, infantile, James typeneuronopathy, distal hereditary motor, type 5
HGNC:4162UniProt:P41250
MPZMyelin protein P0Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Is an adhesion molecule necessary for normal myelination in the peripheral nervous system. It mediates adhesion between adjacent myelin wraps and ultimately drives myelin compaction

LOCALIZAÇÃO

Cell membraneMyelin membrane

VIAS BIOLÓGICAS (1)
EGR2 and SOX10-mediated initiation of Schwann cell myelination
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, demyelinating, type 1B

A dominant demyelinating form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Demyelinating neuropathies are characterized by severely reduced nerve conduction velocities (less than 38 m/sec), segmental demyelination and remyelination with onion bulb formations on nerve biopsy, slowly progressive distal muscle atrophy and weakness, absent deep tendon reflexes, and hollow feet.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
5300.7 TPM
Cólon sigmoide
34.0 TPM
Esôfago - Junção
31.7 TPM
Esôfago - Muscular
30.5 TPM
Artéria coronária
19.6 TPM
OUTRAS DOENÇAS (9)
Roussy-Levy syndromeneuropathy, congenital hypomyelinating, 2Charcot-Marie-Tooth disease dominant intermediate DCharcot-Marie-Tooth disease type 2I
HGNC:7225UniProt:P25189
YARS1Tyrosine--tRNA ligase, cytoplasmicDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Tyrosine--tRNA ligase that catalyzes the attachment of tyrosine to tRNA(Tyr) in a two-step reaction: tyrosine is first activated by ATP to form Tyr-AMP and then transferred to the acceptor end of tRNA(Tyr) (Probable) (PubMed:25533949). Also acts as a positive regulator of poly-ADP-ribosylation in the nucleus, independently of its tyrosine--tRNA ligase activity (PubMed:25533949). Activity is switched upon resveratrol-binding: resveratrol strongly inhibits the tyrosine--tRNA ligase activity and pr

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (1)
Cytosolic tRNA aminoacylation
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, dominant intermediate C

A form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. The dominant intermediate type C is characterized by clinical and pathologic features intermediate between demyelinating and axonal peripheral neuropathies, and motor median nerve conduction velocities ranging from 25 to 45 m/sec.

OUTRAS DOENÇAS (2)
neurologic, endocrine, and pancreatic disease, multisystem, infantile-onset 2Charcot-Marie-Tooth disease dominant intermediate C
HGNC:12840UniProt:P54577
HSPB1Heat shock protein beta-1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Small heat shock protein which functions as a molecular chaperone probably maintaining denatured proteins in a folding-competent state (PubMed:10383393, PubMed:20178975). Plays a role in stress resistance and actin organization (PubMed:19166925). Through its molecular chaperone activity may regulate numerous biological processes including the phosphorylation and the axonal transport of neurofilament proteins (PubMed:23728742)

LOCALIZAÇÃO

CytoplasmNucleusCytoplasm, cytoskeleton, spindle

VIAS BIOLÓGICAS (4)
VEGFA-VEGFR2 PathwayExtra-nuclear estrogen signalingAUF1 (hnRNP D0) binds and destabilizes mRNAMAPK6/MAPK4 signaling
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, axonal, type 2F

A dominant axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy. Onset of Charcot-Marie-Tooth disease type 2F is between 15 and 25 years with muscle weakness and atrophy usually beginning in feet and legs (peroneal distribution). Upper limb involvement occurs later.

EXPRESSÃO TECIDUAL(Ubíquo)
Esôfago - Mucosa
4133.9 TPM
Aorta
3780.0 TPM
Vagina
3375.9 TPM
Artéria tibial
2663.4 TPM
Artéria coronária
2497.0 TPM
OUTRAS DOENÇAS (3)
Charcot-Marie-Tooth disease axonal type 2Fneuronopathy, distal hereditary motor, type 2Bdistal hereditary motor neuropathy type 2
HGNC:5246UniProt:P04792
PRPS1Ribose-phosphate pyrophosphokinase 1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Catalyzes the synthesis of phosphoribosylpyrophosphate (PRPP) that is essential for nucleotide synthesis

LOCALIZAÇÃO

VIAS BIOLÓGICAS (1)
5-Phosphoribose 1-diphosphate biosynthesis
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
78.0 TPM
Cérebro - Hemisfério cerebelar
64.3 TPM
Fibroblastos
58.6 TPM
Cerebelo
51.2 TPM
Tireoide
51.1 TPM
OUTRAS DOENÇAS (8)
phosphoribosylpyrophosphate synthetase superactivityCharcot-Marie-Tooth disease X-linked recessive 5Arts syndromehearing loss, X-linked 1
HGNC:9462UniProt:P60891
AIFM1Apoptosis-inducing factor 1, mitochondrialDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Functions both as NADH oxidoreductase and as regulator of apoptosis (PubMed:17094969, PubMed:20362274, PubMed:23217327, PubMed:33168626). In response to apoptotic stimuli, it is released from the mitochondrion intermembrane space into the cytosol and to the nucleus, where it functions as a proapoptotic factor in a caspase-independent pathway (PubMed:20362274). Release into the cytoplasm is mediated upon binding to poly-ADP-ribose chains (By similarity). The soluble form (AIFsol) found in the nuc

LOCALIZAÇÃO

Mitochondrion intermembrane spaceMitochondrion inner membraneCytoplasmNucleusCytoplasm, perinuclear regionMitochondrionCytoplasm, cytosol

MECANISMO DE DOENÇA

Combined oxidative phosphorylation deficiency 6

A mitochondrial disease resulting in a neurodegenerative disorder characterized by psychomotor delay, hypotonia, areflexia, muscle weakness and wasting. Some patients manifest prenatal ventriculomegaly and severe postnatal encephalomyopathy.

OUTRAS DOENÇAS (4)
X-linked hereditary sensory and autonomic neuropathy with hearing lossCharcot-Marie-Tooth disease X-linked recessive 4spondyloepimetaphyseal dysplasia, Bieganski typesevere X-linked mitochondrial encephalomyopathy
HGNC:8768UniProt:O95831
NDRG1Protein NDRG1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Stress-responsive protein involved in hormone responses, cell growth, and differentiation. Acts as a tumor suppressor in many cell types. Necessary but not sufficient for p53/TP53-mediated caspase activation and apoptosis. Has a role in cell trafficking, notably of the Schwann cell, and is necessary for the maintenance and development of the peripheral nerve myelin sheath. Required for vesicular recycling of CDH1 and TF. May also function in lipid trafficking. Protects cells from spindle disrupt

LOCALIZAÇÃO

Cytoplasm, cytosolCytoplasm, cytoskeleton, microtubule organizing center, centrosomeNucleusCell membrane

VIAS BIOLÓGICAS (1)
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, demyelinating, type 4D

A recessive demyelinating form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Demyelinating neuropathies are characterized by severely reduced nerve conduction velocities (less than 38 m/sec), segmental demyelination and remyelination with onion bulb formations on nerve biopsy, slowly progressive distal muscle atrophy and weakness, absent deep tendon reflexes, and hollow feet. By convention autosomal recessive forms of demyelinating Charcot-Marie-Tooth disease are designated CMT4.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
816.8 TPM
Brain Spinal cord cervical c-1
440.5 TPM
Vagina
430.1 TPM
Esôfago - Mucosa
405.9 TPM
Skin Not Sun Exposed Suprapubic
403.3 TPM
OUTRAS DOENÇAS (1)
Charcot-Marie-Tooth disease type 4D
HGNC:7679UniProt:Q92597
NEFLNeurofilament light polypeptideDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Neurofilaments usually contain three intermediate filament proteins: NEFL, NEFM, and NEFH which are involved in the maintenance of neuronal caliber. May additionally cooperate with the neuronal intermediate filament proteins PRPH and INA to form neuronal filamentous networks (By similarity)

LOCALIZAÇÃO

Cell projection, axonCytoplasm, cytoskeleton

VIAS BIOLÓGICAS (6)
RAF/MAP kinase cascadeRas activation upon Ca2+ influx through NMDA receptorUnblocking of NMDA receptors, glutamate binding and activationLong-term potentiationNegative regulation of NMDA receptor-mediated neuronal transmission
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, demyelinating, type 1F

A dominant demyelinating form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Demyelinating neuropathies are characterized by severely reduced nerve conduction velocities (less than 38 m/sec), segmental demyelination and remyelination with onion bulb formations on nerve biopsy, slowly progressive distal muscle atrophy and weakness, absent deep tendon reflexes, and hollow feet. CMT1F is characterized by onset in infancy or childhood (range 1 to 13 years).

EXPRESSÃO TECIDUAL(Tecido-específico)
Brain Frontal Cortex BA9
487.2 TPM
Córtex cerebral
328.6 TPM
Brain Anterior cingulate cortex BA24
195.3 TPM
Hipotálamo
136.9 TPM
Substância negra
100.6 TPM
OUTRAS DOENÇAS (4)
Charcot-Marie-Tooth disease type 1FCharcot-Marie-Tooth disease, dominant intermediate GCharcot-Marie-Tooth disease type 2ECharcot-Marie-Tooth disease type 2B5
HGNC:7739UniProt:P07196
GNB4Guanine nucleotide-binding protein subunit beta-4Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Guanine nucleotide-binding proteins (G proteins) are involved as a modulator or transducer in various transmembrane signaling systems. The beta and gamma chains are required for the GTPase activity, for replacement of GDP by GTP, and for G protein-effector interaction

LOCALIZAÇÃO

VIAS BIOLÓGICAS (10)
Extra-nuclear estrogen signalingGPER1 signalingThromboxane signalling through TP receptorADORA2B mediated anti-inflammatory cytokines productionProstacyclin signalling through prostacyclin receptor
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, dominant intermediate F

A form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. CMTDIF is characterized by onset around adolescence of slowly progressive distal muscle atrophy and weakness affecting the upper and lower limbs and resulting in steppage gait. There is distal sensory impairment with decreased reflexes. Nerve conduction velocities are variable, ranging from the demyelinating to the axonal range.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
43.9 TPM
Aorta
29.5 TPM
Skin Not Sun Exposed Suprapubic
27.7 TPM
Skin Sun Exposed Lower leg
26.6 TPM
Esôfago - Muscular
25.8 TPM
OUTRAS DOENÇAS (1)
Charcot-Marie-Tooth disease dominant intermediate F
HGNC:20731UniProt:Q9HAV0
INF2Inverted formin-2Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Severs actin filaments and accelerates their polymerization and depolymerization

LOCALIZAÇÃO

Cytoplasm, perinuclear region

MECANISMO DE DOENÇA

Focal segmental glomerulosclerosis 5

A renal pathology defined by the presence of segmental sclerosis in glomeruli and resulting in proteinuria, reduced glomerular filtration rate and progressive decline in renal function. Renal insufficiency often progresses to end-stage renal disease, a highly morbid state requiring either dialysis therapy or kidney transplantation.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
204.3 TPM
Artéria tibial
83.2 TPM
Artéria coronária
78.6 TPM
Aorta
69.0 TPM
Brain Spinal cord cervical c-1
68.8 TPM
OUTRAS DOENÇAS (3)
Charcot-Marie-Tooth disease dominant intermediate Efocal segmental glomerulosclerosis 5familial idiopathic steroid-resistant nephrotic syndrome
HGNC:23791UniProt:Q27J81
IGHMBP2DNA-binding protein SMUBP-2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

5' to 3' helicase that unwinds RNA and DNA duplexes in an ATP-dependent reaction (PubMed:19158098, PubMed:22999958, PubMed:30218034). Specific to 5'-phosphorylated single-stranded guanine-rich sequences (PubMed:22999958, PubMed:8349627). May play a role in RNA metabolism, ribosome biogenesis or initiation of translation (PubMed:19158098, PubMed:19299493). May play a role in regulation of transcription (By similarity). Interacts with tRNA-Tyr (PubMed:19299493)

LOCALIZAÇÃO

NucleusCytoplasmCell projection, axon

MECANISMO DE DOENÇA

Neuronopathy, distal hereditary motor, autosomal recessive 1

A form of distal hereditary motor neuronopathy, a heterogeneous group of neuromuscular disorders caused by selective degeneration of motor neurons in the anterior horn of the spinal cord, without sensory deficit in the posterior horn. The overall clinical picture consists of a classical distal muscular atrophy syndrome in the legs without clinical sensory loss. The disease starts with weakness and wasting of distal muscles of the anterior tibial and peroneal compartments of the legs. Later on, weakness and atrophy may expand to the proximal muscles of the lower limbs and/or to the distal upper limbs.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
48.4 TPM
Cólon sigmoide
33.5 TPM
Esôfago - Junção
31.9 TPM
Útero
29.7 TPM
Cerebelo
29.6 TPM
OUTRAS DOENÇAS (2)
autosomal recessive distal spinal muscular atrophy 1Charcot-Marie-Tooth disease axonal type 2S
HGNC:5542UniProt:P38935
NEFHNeurofilament heavy polypeptideDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Neurofilaments usually contain three intermediate filament proteins: NEFL, NEFM, and NEFH which are involved in the maintenance of neuronal caliber. NEFH has an important function in mature axons that is not subserved by the two smaller NF proteins. May additionally cooperate with the neuronal intermediate filament proteins PRPH and INA to form neuronal filamentous networks (By similarity)

LOCALIZAÇÃO

Cytoplasm, cytoskeletonCell projection, axon

MECANISMO DE DOENÇA

Amyotrophic lateral sclerosis

A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases.

EXPRESSÃO TECIDUAL(Ubíquo)
Próstata
158.9 TPM
Brain Frontal Cortex BA9
104.3 TPM
Córtex cerebral
67.0 TPM
Hipotálamo
63.3 TPM
Substância negra
56.2 TPM
OUTRAS DOENÇAS (3)
Charcot-Marie-Tooth disease axonal type 2CCamyotrophic lateral sclerosisamyotrophic lateral sclerosis type 1
HGNC:7737UniProt:P12036
EGR2E3 SUMO-protein ligase EGR2Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Sequence-specific DNA-binding transcription factor (PubMed:17717711). Plays a role in hindbrain segmentation by regulating the expression of a subset of homeobox containing genes and in Schwann cell myelination by regulating the expression of genes involved in the formation and maintenance of myelin (By similarity). Binds to two EGR2-consensus sites EGR2A (5'-CTGTAGGAG-3') and EGR2B (5'-ATGTAGGTG-3') in the HOXB3 enhancer and promotes HOXB3 transcriptional activation (By similarity). Binds to sp

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (4)
Activation of anterior HOX genes in hindbrain development during early embryogenesisTranscriptional regulation of white adipocyte differentiationNGF-stimulated transcriptionEGR2 and SOX10-mediated initiation of Schwann cell myelination
MECANISMO DE DOENÇA

Neuropathy, congenital hypomyelinating, 1, autosomal recessive

A severe degenerating neuropathy that results from a congenital impairment in myelin formation. It is clinically characterized by early onset of hypotonia, areflexia, distal muscle weakness, and very slow nerve conduction velocities (as low as 3m/s). Some patients manifest nearly complete absence of spontaneous limb movements, respiratory distress at birth, and complete absence of myelin shown by electron microscopy of peripheral nerves.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
62.6 TPM
Linfócitos
32.8 TPM
Skin Not Sun Exposed Suprapubic
16.8 TPM
Skin Sun Exposed Lower leg
11.0 TPM
Pulmão
7.8 TPM
OUTRAS DOENÇAS (3)
Charcot-Marie-Tooth disease type 4ECharcot-Marie-Tooth disease type 1DCharcot-Marie-Tooth disease type 3
HGNC:3239UniProt:P11161

Medicamentos e terapias

NALTREXONE HYDROCHLORIDEPhase 3

Mecanismo: Opioid receptors; mu/kappa/delta antagonist

NALTREXONEPhase 3

Mecanismo: Opioid receptors; mu/kappa/delta antagonist

BACLOFENPhase 3

Mecanismo: GABA-B receptor agonist

ULIPRISTAL ACETATEPhase 2

Mecanismo: Progesterone receptor modulator

MEXILETINEPhase 2

Mecanismo: Sodium channel alpha subunit blocker

EPALRESTATPhase 2

Mecanismo: Aldose reductase inhibitor

Ver mais no OpenTargets

Variantes genéticas (ClinVar)

658 variantes patogênicas registradas no ClinVar.

🧬 PMP22: GRCh38/hg38 17p12(chr17:14174654-15579519)x1 ()
🧬 PMP22: GRCh38/hg38 17p12(chr17:14170219-15510549)x3 ()
🧬 PMP22: GRCh38/hg38 17p12(chr17:14184601-15581021)x1 ()
🧬 PMP22: GRCh38/hg38 17p12(chr17:14174654-15536883)x3 ()
🧬 PMP22: GRCh38/hg38 17p12(chr17:14191318-15520772)x3 ()
Ver todas no ClinVar

Vias biológicas (Reactome)

192 vias biológicas associadas aos genes desta condição.

Glyoxylate metabolism and glycine degradation Class I peroxisomal membrane protein import Selenoamino acid metabolism Cytosolic tRNA aminoacylation Mitochondrial tRNA aminoacylation Transcriptional and post-translational regulation of MITF-M expression and activity Translesion Synthesis by POLH HSF1 activation ABC-family proteins mediated transport N-glycan trimming in the ER and Calnexin/Calreticulin cycle Hedgehog ligand biogenesis Hh mutants are degraded by ERAD Defective CFTR causes cystic fibrosis Josephin domain DUBs Ovarian tumor domain proteases Neutrophil degranulation E3 ubiquitin ligases ubiquitinate target proteins Protein methylation Neddylation RHOH GTPase cycle Aggrephagy Attachment and Entry Attachment and Entry KEAP1-NFE2L2 pathway Dengue Virus Genome Translation and Replication AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide Metabolism of Angiotensinogen to Angiotensins Physiological factors Developmental Lineage of Mammary Gland Myoepithelial Cells Regulation of pyruvate dehydrogenase (PDH) complex Signaling by Retinoic Acid Interferon gamma signaling COPII-mediated vesicle transport Signaling by ALK fusions and activated point mutants PMP22 PMP22 Gene PMP22 gene expression EGR2, SOX10 and TEAD1 bind enhancers in the PMP22 gene PMP22 gene:EGR2:SOX10:TEAD1:WWTR1,YAP1 Fatty acyl-CoA biosynthesis Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex Toll Like Receptor 4 (TLR4) Cascade Retrograde neurotrophin signalling Gap junction degradation Formation of annular gap junctions NOSTRIN mediated eNOS trafficking MHC class II antigen presentation Lysosome Vesicle Biogenesis Golgi Associated Vesicle Biogenesis Recycling pathway of L1 Clathrin-mediated endocytosis NGF-stimulated transcription Degradation of CDH1 Insulin processing RHO GTPases activate KTN1 COPI-dependent Golgi-to-ER retrograde traffic Kinesins APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway Acyl chain remodeling of DAG and TAG Triglyceride biosynthesis MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis PLC beta mediated events Effects of PIP2 hydrolysis Elevation of cytosolic Ca2+ levels DAG and IP3 signaling Role of phospholipids in phagocytosis FCERI mediated Ca+2 mobilization Glucagon-like Peptide-1 (GLP1) regulates insulin secretion Ca2+ pathway Regulation of insulin secretion VEGFR2 mediated cell proliferation Ion homeostasis CLEC7A (Dectin-1) induces NFAT activation FCGR3A-mediated IL10 synthesis Sensory perception of sweet, bitter, and umami (glutamate) taste Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Cytosolic sensors of pathogen-associated DNA RNA Polymerase III Chain Elongation RNA Polymerase III Transcription Termination RNA Polymerase III Abortive And Retractive Initiation RNA Polymerase III Transcription Initiation From Type 1 Promoter RNA Polymerase III Transcription Initiation From Type 2 Promoter RNA Polymerase III Transcription Initiation From Type 3 Promoter TRP channels High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells Complex IV assembly Meiotic synapsis Nuclear Envelope Breakdown Initiation of Nuclear Envelope (NE) Reformation Breakdown of the nuclear lamina XBP1(S) activates chaperone genes Depolymerization of the Nuclear Lamina Signaling by BRAF and RAF1 fusions Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Peroxisomal protein import Synthesis of PIPs at the ER membrane Synthesis of PIPs at the plasma membrane Synthesis of PIPs at the early endosome membrane Synthesis of PIPs at the late endosome membrane TP53 Regulates Metabolic Genes Respiratory electron transport Cytoprotection by HMOX1 Elastic fibre formation Molecules associated with elastic fibres trans-Golgi Network Vesicle Budding VxPx cargo-targeting to cilium COPI-mediated anterograde transport Assembly and Release of Dengue Virus Virions Dengue Virus-Host Interactions OADH complex synthesizes glutaryl-CoA from 2-OA Ion transport by P-type ATPases Potential therapeutics for SARS HSF1-dependent transactivation Activated NOTCH1 Transmits Signal to the Nucleus Constitutive Signaling by NOTCH1 PEST Domain Mutants Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant Constitutive Signaling by NOTCH1 HD Domain Mutants Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants NOTCH2 Activation and Transmission of Signal to the Nucleus RUNX3 regulates NOTCH signaling RAC1 GTPase cycle RAC3 GTPase cycle NOTCH3 Activation and Transmission of Signal to the Nucleus NOTCH4 Activation and Transmission of Signal to the Nucleus Nephron development PINK1-PRKN Mediated Mitophagy RHOT2 GTPase cycle Factors involved in megakaryocyte development and platelet production NRAGE signals death through JNK G alpha (12/13) signalling events CDC42 GTPase cycle EGR2 and SOX10-mediated initiation of Schwann cell myelination RHOA GTPase cycle RND3 GTPase cycle RND1 GTPase cycle Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal Separation of Sister Chromatids Resolution of Sister Chromatid Cohesion Regulation of PLK1 Activity at G2/M Transition HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand Loss of Nlp from mitotic centrosomes Recruitment of mitotic centrosome proteins and complexes Loss of proteins required for interphase microtubule organization from the centrosome Recruitment of NuMA to mitotic centrosomes Anchoring of the basal body to the plasma membrane RHO GTPases Activate Formins COPI-independent Golgi-to-ER retrograde traffic Mitotic Prometaphase AURKA Activation by TPX2 HCMV Early Events EML4 and NUDC in mitotic spindle formation Cation-coupled Chloride cotransporters Defective SLC12A6 causes agenesis of the corpus callosum, with peripheral neuropathy (ACCPN) VEGFA-VEGFR2 Pathway AUF1 (hnRNP D0) binds and destabilizes mRNA MAPK6/MAPK4 signaling Extra-nuclear estrogen signaling 5-Phosphoribose 1-diphosphate biosynthesis TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain Unblocking of NMDA receptors, glutamate binding and activation Ras activation upon Ca2+ influx through NMDA receptor RAF/MAP kinase cascade Assembly and cell surface presentation of NMDA receptors Negative regulation of NMDA receptor-mediated neuronal transmission Long-term potentiation Activation of G protein gated Potassium channels Glucagon signaling in metabolic regulation G-protein activation ADP signalling through P2Y purinoceptor 12 G beta:gamma signalling through PI3Kgamma Prostacyclin signalling through prostacyclin receptor Adrenaline,noradrenaline inhibits insulin secretion G alpha (q) signalling events G beta:gamma signalling through PLC beta G alpha (s) signalling events ADP signalling through P2Y purinoceptor 1 G alpha (i) signalling events G alpha (z) signalling events Glucagon-type ligand receptors Thromboxane signalling through TP receptor Vasopressin regulates renal water homeostasis via Aquaporins Thrombin signalling through proteinase activated receptors (PARs) Presynaptic function of Kainate receptors Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding G beta:gamma signalling through BTK G beta:gamma signalling through CDC42 GPER1 signaling ADORA2B mediated anti-inflammatory cytokines production Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits Transcriptional regulation of white adipocyte differentiation Activation of anterior HOX genes in hindbrain development during early embryogenesis

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
Aprovado1
3Fase 33
2Fase 23
·Pré-clínico4
Medicamentos catalogadosEnsaios clínicos· 6 medicamentos · 5 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Doença de Charcot-Marie-Tooth/neuropatia sensitiva e motora hereditária

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

5 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
0 papers (10 anos)
#1

Gait Parameters Alterations Under Dual-Task Conditions in Patients With Acquired and Hereditary Peripheral Neuropathies.

European journal of neurology2026 Mar

Peripheral demyelinating neuropathies impair gait and increase fall risk, particularly under cognitively demanding conditions. While gait disturbances in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and Charcot-Marie-Tooth disease type 1A (CMT1A) are well documented, their differential responses to cognitive dual-tasking remain poorly understood. In this prospective study, 62 patients (31 CIDP, 31 CMT1A) performed 10-m barefoot walking trials under three conditions: natural walking, low dual-task (answering factual questions), and high dual-task (introspective questions about illness impact). Gait parameters, including speed, stride length, stride time, foot and heel clearance, were measured using a motion capture system. Group, condition, and interaction effects were analyzed using linear mixed-effects models. Both groups showed significant reductions in gait speed and stride length under dual-task conditions. Compared to CMT1A, CIDP patients exhibited more pronounced slowing and increased stride time, especially during high dual-tasking. Heel clearance decreased significantly in CIDP, with a group × condition interaction, while CMT1A patients maintained more stable gait patterns. Foot clearance at peak swing declined in both groups without intergroup differences. These results suggest that CIDP patients adopt a more cautious gait under cognitive load, reflecting reduced automatism and adaptability. In contrast, CMT1A patients appear to benefit from long-term compensatory strategies developed over the disease course. Moreover, the CIDP patients decreased their heel clearance during dual-task, increasing the fall risk. Dual-task gait analysis reveals distinct adaptations in hereditary and acquired neuropathies. Parameters such as heel clearance and stride time may serve as functional markers to guide diagnosis and rehabilitation.

#2

Development and Validation of a Visual Grading Score of Disease Severity From Gait Videos in Genetic Peripheral Neuropathy.

European journal of neurology2026 Mar

The Clinical Eye Score (CES) is a score to grade disease severity in peripheral neuropathy visually from videos of patients walking. It correlates strongly with state-of-the-art outcome measures for peripheral neuropathy in patients with CMT. Therefore, it may provide a solution for digital or remote follow-up examinations for adult patients with peripheral neuropathies. Monitoring individuals with peripheral neuropathies is challenging due to limited availability and time resources of neurologists, especially for rare genetic forms. This highlights the need for innovative methods to quantify disease severity efficiently and enable telemedical settings. In this study, we explored the feasibility of visual grading of gait disability as a novel approach for remote disease monitoring, using genetic neuropathies (Charcot Marie Tooth Disease, short CMT) as a model. We prospectively evaluated 53 participants with CMT using a battery of clinical examination scores, and patient reported outcome measures (PROMs), as well as semi‐standardized sagittal‐plane videos of participants walking a 4‐m runway for 5 ± 2 min cross‐sectionally, and developed the Visual Gait Assessment Scale in Polyneuropathy (vGASP) to grade the severity of gait abnormality. Three independent raters evaluated the score as easily understandable and quick. The vGASP was internally consistent (inter‐class coefficient of 0.9) and valid when correlating with validated clinical outcome measures (Spearman's ρ = 0.6–0.8). The vGASP may offer a time‐effective solution for remote monitoring of patients in CMT and potentially other gait‐affecting polyneuropathies.

#3

AAVrh74.tMCK.NT-3 Surrogate Gene Therapy in a Mouse Model of CMT2A.

International journal of molecular sciences2026 Feb 18

Mutations in the Mitofusin 2 (MFN2) gene cause Charcot-Marie-Tooth type 2A (CMT2A). Neurotrophin 3 (NT-3) is an autocrine factor that supports Schwann cell survival and differentiation, axon regeneration and myelination, neuromuscular junction (NMJ) integrity, and mitochondrial function. In this study, we assessed the efficacy of NT-3 gene therapy using the AAVrh74 serotype in the Mfn2+/- mouse model for CMT2A. Although haploinsufficiency is not reported in CMT2A patients, our model shows some features of CMT2A, including axonal atrophy, muscle atrophy, length-dependent axon loss, and abnormal mitochondria, in muscle in the enzyme histochemistry. Eight-month-old Mfn2+/- mice received a 3 × 1011 vector genome dose of AAVrh74.tMCK.NT-3 intramuscularly, and functional, electrophysiological, and histological outcomes were assessed six months post-treatment. NT-3 gene therapy in Mfn2+/- mice significantly improved grip strength and rotarod performance, and ameliorated electrophysiological abnormalities and NMJ denervation in lumbrical muscles. Additionally, our therapeutic approach improved muscle histopathology with reductions in mitochondrial abnormalities and oxidative stress. NT-3 further remodeled carbohydrate metabolism in muscle. Our study indicated that AAV.NT-3 gene therapy has a disease-modifying effect in the Mfn2+/- model of CMT2A, providing further support for the translational potential of this surrogate gene therapy approach to CMT2A patients.

#4

Muscle-Specific DNM2 Overexpression Improves Charcot-Marie-Tooth Disease In Vivo and Reveals a Narrow Therapeutic Window in Skeletal Muscle.

International journal of molecular sciences2026 Feb 02

Charcot-Marie-Tooth disease (CMT), caused by dominant loss-of-function mutations in DNM2, encoding the GTPase dynamin-2, impairs motor and sensory function. However, the respective contributions of muscle and nerve pathology, and the therapeutic potential of increasing DNM2 expression, remain unresolved. We evaluated tissue-targeted and systemic approaches to increase DNM2 in a mouse model carrying the common K562E-CMT mutation. Muscle-specific DNM2 overexpression from embryogenesis in Dnm2K562E/+ mice ameliorated desmin and integrin mislocalization, membrane trafficking defects, mitochondrial abnormalities, and fibrosis in skeletal muscle, resulting in improved locomotor coordination despite persistent muscle atrophy. Conversely, systemic postnatal AAV delivery of human DNM2 increased DNM2 in muscle but failed to transduce nerves and paradoxically worsened the muscle pathology, producing centronuclear myopathy-like features. These findings reveal a primary pathogenic impact of DNM2-CMT mutation within skeletal muscle, independent of nerve involvement. Collectively, they underscore that precise DNM2 dosage is critical for neuromuscular homeostasis and reveal a narrow therapeutic window for safe and effective therapeutic intervention. This paradox, in which efforts to compensate for a loss-of-function neuropathy risk inducing a gain-of-function myopathy, highlights the need for tightly controlled modulation of DNM2 activity in future therapeutic strategies.

#5

Stress-Driven Selective Neuronal Vulnerability in Charcot-Marie-Tooth Disease: From Prodromal Pathology to Therapeutic Implications.

Cells2026 Jan 31

Charcot-Marie-Tooth (CMT) disease represents the most prevalent inherited peripheral neuropathy with a broad range of clinical manifestations, inheritance patterns, and causative genes. The primary pathological hallmark is progressive degeneration, predominantly affecting sensory and motor neurons, leading to prominent sensory deficits and progressive motor impairments. While neuropathy-causing mutations in the ubiquitously expressed small heat shock protein HSPB1 account for a subset of axonal CMT cases, the mechanisms underlying the selective vulnerability of peripheral neurons remain poorly understood. In this review, we synthesize emerging evidence to reframe HSPB1-related CMT as a prototypical gene-environment interaction disorder. The unique anatomical exposure and high metabolic demands of the peripheral nervous system (PNS) render it particularly vulnerable to HSPB1 mutation-mediated homeostatic collapse, which manifests through three interconnected pathological axes: proteostatic disturbance, cytoskeletal dysregulation, and mitochondrial dysfunction. Crucially, these deficits converge to impair the stress adaptability of peripheral neurons, creating a maladaptive feedback loop wherein environmental stressors exacerbate intrinsic vulnerabilities. We further propose a phase-specific therapeutic framework that prioritizes early intervention during the clinically silent yet biologically active prodromal stage, when targeted modulation of the HSPB1 chaperone interactome and remodeling neural homeostasis may forestall neurodegeneration. This therapeutic paradigm shift from symptomatic management to preclinical neuroprotection underscores the imperative for precision medicine approaches in future CMT intervention.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC2 artigos no totalmostrando 199

2026

Gait Parameters Alterations Under Dual-Task Conditions in Patients With Acquired and Hereditary Peripheral Neuropathies.

European journal of neurology
2026

Development and Validation of a Visual Grading Score of Disease Severity From Gait Videos in Genetic Peripheral Neuropathy.

European journal of neurology
2026

Behavioral Thermoceptive Responses and Morphologic Correlates in Mouse Models of CMT1A, HNPP, and Aging.

Journal of the peripheral nervous system : JPNS
2026

Cranial Nerve Involvement With Diplopia as Presenting Feature of CMT1H Caused by Recurring FBLN5 Variant.

Journal of the peripheral nervous system : JPNS
2026

AAVrh74.tMCK.NT-3 Surrogate Gene Therapy in a Mouse Model of CMT2A.

International journal of molecular sciences
2026

ABCA1: A Therapeutic Target for Improving Cholesterol Homeostasis in Peripheral Neuropathies.

Biomolecules
2026

Unraveling GDAP1: Bridging Mitochondrial Biology and Peripheral Neuropathy.

Biomolecules
2026

Muscle-Specific DNM2 Overexpression Improves Charcot-Marie-Tooth Disease In Vivo and Reveals a Narrow Therapeutic Window in Skeletal Muscle.

International journal of molecular sciences
2026

Stress-Driven Selective Neuronal Vulnerability in Charcot-Marie-Tooth Disease: From Prodromal Pathology to Therapeutic Implications.

Cells
2026

Patient-derived neural organoids reveal developmental impairments associated with a novel GJB1 mutation in X-linked Charcot-Marie-Tooth disease.

Neurobiology of disease
2026

Genetic commonalities between rare subtypes of ALS and CMT: insights into molecular mechanisms of neurodegeneration.

Amino acids
2026

Hereditary Polyneuropathies in the Era of Precision Medicine: Genetic Complexity and Emerging Strategies.

Genes
2026

White Matter Microstructural Correlates of Auditory Brainstem Responses in Patients With Charcot-Marie-Tooth Disease.

Brain and behavior
2026

TFG p.G269V Mutation Disrupts Motor Neuron Function in iPSC-Derived Models via Wnt Signaling Dysregulation.

Journal of neurochemistry
2026

Charcot-Marie-Tooth disease and related neuropathies.

Nature reviews. Disease primers
2026

Novel Biallelic PLEKHG5 Variant Associated With Intermediate Charcot-Marie-Tooth Disease: Case Report From South America.

Journal of the peripheral nervous system : JPNS
2026

Evaluating Cochlear Implantation Outcomes in Charcot-Marie-Tooth Disease: A Case Series Analysis of Genetic Profiles and Intervention Timing.

Otology &amp; neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
2026

Broadening the Clinical Spectrum of Axonal Hereditary Neuropathies: A Comparative Case Study on DNAJB2- and HINT1-Related Disease.

Journal of the peripheral nervous system : JPNS
2026

Impaired PARP1-dependent DNA repair in MORC2 mutations drives axonal degeneration in Charcot-Marie-Tooth disease subtype 2Z and spinal muscular atrophy-like neuromotor disorders.

Pharmacological research
2026

Clinical and molecular spectrum of an Iranian Charcot-Marie-Tooth 2T cohort, and the diagnostic importance of whole exome sequencing in identifying co-occurrence inherited disorders.

Neuromuscular disorders : NMD
2026

Metabolic signatures in sciatic nerve of PMP22 transgenic rats provide insights into the pathogenesis of charcot-marie-tooth disease type 1 A.

Scientific reports
2026

[Genetic variant analysis in patients with autosomal recessive demyelinating Charcot-Marie-Tooth disease].

Zhonghua nei ke za zhi
2026

Spectrum of dominant Charcot-Marie-Tooth disease due to SLC12A6 variants.

Journal of neurology, neurosurgery, and psychiatry
2026

Aberrant Complement Activation Is a Prominent Feature of Chronic Inflammatory Demyelinating Polyneuropathy.

Neurology(R) neuroimmunology &amp; neuroinflammation
2026

AAV9 gene therapy optimization for SMARD1/CMT2S: safety and long-term efficacy comparison of two vectors in a SMARD1 preclinical model.

Journal of biomedical science
2026

Phenotypic continuum in IGHMBP2-related disorders: a portfolio of cases from typical to Guillain-Barré syndrome-like presentation.

Neuromuscular disorders : NMD
2026

Aberrant Molecular Myelin Architecture in Charcot-Marie-Tooth Disease Type 1A and Hereditary Neuropathy With Liability to Pressure Palsies.

Glia
2026

[A case of neuronal intranuclear inclusion disease presenting with leukoencephalopathy after the diagnosis of Charcot-Marie-Tooth disease type 4C].

Rinsho shinkeigaku = Clinical neurology
2025

Novel Dominant Splicing Variant in MPZ Associated With Unusual Charcot-Marie-Tooth Disease.

Journal of the peripheral nervous system : JPNS
2025

Relationships of GDAP1 Mutations to Disease Phenotype and Mechanisms of Therapeutic Action of Oxidative Metabolism Activators in a Patient with Charcot-Marie-Tooth Neuropathy Type 2K.

Biochemistry. Biokhimiia
2025

Lipid dependence of connexin-32 gap junction channel conformations.

Nature communications
2025

Abnormal fat distribution in two patients with RAB7A-associated Charcot-Marie-Tooth type 2B: a case report.

BMC neurology
2025

PMP22-Related Neuropathies: A Systematic Review.

Genes
2025

Genetic profile of Charcot-Marie-Tooth disease in the Saudi population: A retrospective study highlighting the role of consanguinity.

Neurosciences (Riyadh, Saudi Arabia)
2025

Drug repurposing screen identifies an HRI activating compound that promotes adaptive mitochondrial remodeling in MFN2-deficient cells.

Proceedings of the National Academy of Sciences of the United States of America
2025

The Ighmbp2-R604X mouse presents with the most severe SMARD1 clinical symptoms resulting in failure to thrive, respiratory and feeding deficits, aspiration and severe axon and muscle pathology.

Neurobiology of disease
2026

Haplotype editing with CRISPR-Cas9 as a therapeutic approach for dominant-negative missense mutations in NEFL.

Molecular therapy : the journal of the American Society of Gene Therapy
2025

Frequent De Novo Mutations in Korean Patients With Charcot-Marie-Tooth Disease.

Journal of the peripheral nervous system : JPNS
2026

Peripheral Neuropathy: A Review.

JAMA
2025

Validation and Reliability of the Thai Pediatric Charcot-Marie-Tooth Quality of Life Outcome Measure.

Journal of the peripheral nervous system : JPNS
2025

Advances and challenges in modeling Charcot-Marie-Tooth type 2A using iPSC-derived models.

Stem cell reports
2025

[Charcot-Marie-Tooth Disease: Historical Evolution and Present Understanding].

Brain and nerve = Shinkei kenkyu no shinpo
2025

Unraveling the Overlapping Spectrum of Hereditary Neuropathies: Clinical and Genetic Insights From the UAE.

Cureus
2025

Phenotypic spectrum of variants in the FIG4 gene: variants associated with Charcot-Marie-Tooth 4J and parkinsonism.

European journal of medical genetics
2025

Evaluation of normalized T1 signal intensity obtained using an automated segmentation model in lower leg MRI as a potential imaging biomarker in Charcot-Marie-Tooth disease type 1 A.

Scientific reports
2025

Novel GNB4 Gene Variant and the Spectrum of GNB4 Variants in Patients With Charcot-Marie-Tooth Disease.

Neurology. Genetics
2025

Inherited Peripheral Neuropathies.

Neurologic clinics
2025

Charcot-Marie-Tooth Disease With Severe Hand Contractures and Respiratory Failure Requiring Long-Term Ventilator Support: A Case Report.

Cureus
2025

Is gaitrite system sensitive in discriminating gait pattern of subjects affected by Charcot Marie tooth? A pilot study.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2025

A systematic review of CRISPR applications in demyelinating peripheral nervous system disorders.

Regenerative medicine
2025

Multidimensional evaluation of clinical and functional impairment in a large population of patients with Charcot-Marie-Tooth.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2025

Statistical Shape Modeling Characterization of Cavovarus Deformity Between Demyelinating and Axonal Subtypes of Charcot-Marie-Tooth Disease.

Foot &amp; ankle international
2025

Biallelic variants in ARHGAP19 cause a progressive inherited motor-predominant neuropathy.

The Journal of clinical investigation
2025

Comparison of the presentation and electrophysiological characteristics of autoimmune nodopathies in patients with antibody-negative CIDP and CMT1.

Frontiers in neurology
2026

A novel homozygous COX6A1 variant causes axonal charcot-marie-tooth disease, developmental delays and mitochondrial dysfunction.

Journal of human genetics
2025

The Easy Handgrip Test as a Tool for Assessing Motor Fatigability in Children With Charcot-Marie-Tooth Disease Type 1A.

Journal of the peripheral nervous system : JPNS
2025

Surgical correction of foot deformities in Charcot-Marie-Tooth-disease: effects on personal goals and gait capacity.

Neuromuscular disorders : NMD
2026

Nationwide Characterization of MFN2-Related CMT in 176 Japanese Patients: Clinical and Genetic Insights.

Annals of clinical and translational neurology
2025

[A case of X-linked Charcot-Marie-Tooth disease type 1 (CMTX1) diagnosed based on recurrent brain lesions despite peripheral neuropathy responsive to immunotherapy].

Rinsho shinkeigaku = Clinical neurology
2025

Ocular Surface Changes Associated with Neurological Diseases.

Medicina (Kaunas, Lithuania)
2025

Selective mitophagy activation and protein aggregate accumulation in MTMR5/SBF1-deficient fibroblasts.

Life sciences
2025

Charcot-Marie-Tooth type 2A variants of mitofusin 2 sensitize cells to apoptotic cell death.

Journal of cell science
2025

Advances and Clues of Nutritional Adjuvant Therapy for Charcot-Marie-Tooth Disease.

The Journal of nutrition
2026

INF2-Related Charcot-Marie-Tooth Disease in a Japanese Cohort: Genetic and Clinical Insights.

Annals of clinical and translational neurology
2025

Designing and Implementing a Web-Based Platform for Accurate and Reliable Clinical Outcome Measures and Global Certification for Evaluating Charcot-Marie-Tooth disease.

Journal of the peripheral nervous system : JPNS
2025

Electrophysiological findings in SH3TC2 neuropathy mimicking inflammatory neuropathies.

Journal of neurology, neurosurgery, and psychiatry
2025

Elastin Microfibril Interface-Located Protein 1 (EMILIN1) Mutation Mimicking Axonal Hereditary Motor Sensory Neuropathy.

Cureus
2025

A Family With X-Linked Charcot-Marie-Tooth Disease Type 1: A Case for Reclassifying a Variant of Uncertain Significance in GJB1and Review of the Literature.

Journal of clinical neuromuscular disease
2025

Anaesthetic management using remimazolam in a patient with Charcot-Marie-Tooth disease complicated by sarcoidosis.

BMJ case reports
2025

Generation and characterization of a patient-derived iPSC line, CSSi022-A (15666), with a pathogenic MFN2 mutation causing Charcot-Marie-Tooth disease type 2A.

Stem cell research
2025

Genotypic and Phenotypic Characterization of Axonal Charcot-Marie-Tooth Disease in Childhood: Identification of One Novel and Four Known Mutations.

Genes
2025

Two Cases of Charcot-Marie-Tooth Disease Diagnosed in a 53-Year-Old Mother and a 24-Year-Old Daughter.

The American journal of case reports
2026

Targeted plasma proteomics uncover proteins associated with KIF5A-linked SPG10 and ALS spectrum disorders.

HGG advances
2025

The current status of Charcot-Marie-Tooth disease type 1 A treatment.

Acta neurologica Belgica
2025

Longitudinal assessment of natural disease progression in Brazilian children and adolescents with Charcot-Marie-Tooth disease.

Arquivos de neuro-psiquiatria
2025

SARM1 Inhibition in Three Mouse Models of Charcot-Marie-Tooth Disease.

Journal of the peripheral nervous system : JPNS
2026

Biallelic variants in COX18 cause a mitochondrial disorder primarily manifesting as peripheral neuropathy.

Brain : a journal of neurology
2025

Untargeted lipidomic deep-profiling of human plasma via high-performance aza-Prilezhaev aziridination-LC-MS: Unraveling CC isomeric signatures of Charcot-Marie-Tooth disease.

Analytica chimica acta
2025

Functional reorganization of the visual cortex in patients with Charcot-Marie-Tooth disease: A multimodal neuroimaging study.

Brain research bulletin
2025

Biallelic Variants in the DARS2 Gene as a Novel Cause of Axonal Charcot-Marie-Tooth Disease.

Annals of neurology
2025

Genetic Deletion of Sarm1 in Mouse Models of Three Neurological Diseases.

Journal of the peripheral nervous system : JPNS
2025

Mitochondrial Trifunctional Protein Deficiency due to HADHA Variants Masquerading as Charcot-Marie-Tooth Disease.

Journal of the peripheral nervous system : JPNS
2025

Circulating mitochondrial components and metabolic and inflammatory markers in Charcot-Marie-Tooth type 2B.

Neurobiology of disease
2025

Estradiol rescues male hydroxyl radical-mediated Charcot-Marie-Tooth 2Z by Morc2a stabilization through autophagy inhibition in a murine model.

Acta neuropathologica
2025

Macrophage Targeting Protects Nerve Structure and Improves Muscle Innervation in a Mouse Model of Charcot-Marie-Tooth 2J.

Glia
2025

Nationwide Phenotypic and Genotypic Characterisation of 103 Patients With SH3TC2 Gene-Related Demyelinating Peripheral Neuropathy.

European journal of neurology
2026

Metabolic Syndrome in Ambulatory People With Post-Polio Syndrome, Charcot-Marie-Tooth Disease, and Other Neuromuscular Diseases.

American journal of physical medicine &amp; rehabilitation
2025

Plantar Pressure Distribution in Charcot-Marie-Tooth Disease: A Systematic Review.

Sensors (Basel, Switzerland)
2025

Physical Therapy Interventions for Gait and Balance in Charcot-Marie-Tooth Disease: A Scoping Review.

Life (Basel, Switzerland)
2025

Further delineation of LRSAM1-related Charcot-Marie-Tooth type 2P with parkinsonism.

European journal of medical genetics
2025

GDAP1-Related Charcot-Marie-Tooth Disease: Axonal or Demyelinating Subtype? Autosomal Recessive or Autosomal Dominant Inheritance?

Journal of the peripheral nervous system : JPNS
2025

Charcot-Marie-Tooth-like presentation in giant axonal neuropathy: clinical variability and prevalence in a large Japanese case series.

Journal of neurology
2025

Acute adrenal insufficiency-induced hypotension following spinal surgery in a pediatric patient with Charcot-Marie-Tooth disease and severe scoliosis: a case report.

BMC pediatrics
2025

Clinical Characteristics of Gait Disturbance in Charcot-Marie-Tooth Disease and Future Directions in Physical Therapy.

Cureus
2025

Novel neurofilament light (Nefl) E397K mouse models of Charcot-Marie-tooth type 2E (CMT2E) present early and chronic axonal neuropathy.

Human molecular genetics
2025

Increased BNIP3-mediated mitophagy attenuates GDAP1 loss of function - implications for Charcot-Marie-Tooth disease 4A.

Neurobiology of disease
2025

Digenesis in Charcot-Marie-Tooth Disease: Impact of Combined Mutations in the MFN2 and GDAP1 Genes.

Journal of the peripheral nervous system : JPNS
2025

Plasma periaxin is a biomarker of peripheral nerve demyelination.

Brain : a journal of neurology
2025

New variants and genotype-phenotype correlation in KIF5A mutation: the contribution of a large Italian cohort.

Journal of medical genetics
2026

Intrafamilial Phenotypic Variation in Taiwanese Patients with Hereditary Spastic Paraplegia and Charcot-Marie-Tooth Disease Due to KIF5A Mutations: A Cross-Sectional Observational Study.

Acta neurologica Taiwanica
2025

Nerve Diameter and DTI Parameters Maybe Potential Markers for Clinical Trial in Patients With Charcot-Marie-Tooth Disease Type 1A.

European journal of neurology
2025

Disease spectrum and long-term prognosis of patients with BAG3-associated neuromuscular diseases in Europe.

Brain : a journal of neurology
2026

Charcot-Marie-Tooth disease type 1E: clinical natural history and molecular impact of PMP22 variants.

Brain : a journal of neurology
2025

[Phenotypic heterogeneity of Charcot-Marie-Tooth type 2A disease associated with the c.1091G>C missense mutation (p.Arg364Pro) in the MFN2 gene].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
2026

Sonographic Muscle Thickness Assessment Correlates With Disease Burden and Progression in Charcot-Marie-Tooth 1A Disease.

Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society
2025

The NeflE397K mouse model demonstrates muscle pathology and motor function deficits consistent with CMT2E.

Human molecular genetics
2025

Combining dynamin 2 myopathy and neuropathy mutations rescues both phenotypes.

Nature communications
2025

Feasibility, Validity, and Reliability of the Virtual CMT Infant Toddler Scale (vCMTInfS): A Remote Evaluation of Infants/Toddlers With CMT.

Journal of the peripheral nervous system : JPNS
2025

First Iranian Family with a Novel Missense Variant in MYO9B Gene Causing Charcot-Marie-Tooth Disease.

Archives of Iranian medicine
2025

Clinical and Genetic Landscape of IGHMBP2 -Related Disorders: From Novel Variants to Phenotypic Insights.

American journal of medical genetics. Part A
2025

Split Hand Syndrome in Charcot-Marie-Tooth Disease Type X1 (CMTX1): A Clinical, Neurophysiological, and Radiological Study.

European journal of neurology
2025

Video head impulse test findings in patients with peripheral myelin protein 22 related neuropathies.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
2025

Rare Variants Cause Charcot-Marie-Tooth Disease in Malian Families.

Brain and behavior
2025

A Novel Mutation in CNTNAP1 Gene Causes Disorganization of Axonal Domains, Hypomyelination and Severe Neurological Deficits.

Journal of neuroscience research
2025

Genetic and clinical spectrum of early growth response 2-related Charcot-Marie-Tooth disease in a Brazilian cohort.

Arquivos de neuro-psiquiatria
2025

De novo somatic mosaicisms of INF2 and TRPV4 in patients with Charcot-Marie-Tooth disease.

Genes &amp; genomics
2025

The Spectrum of Small Heat Shock Protein B8 (HSPB8)-Associated Neuromuscular Disorders.

International journal of molecular sciences
2025

Therapeutic sphingosine-1-phosphate receptor modulation by repurposing fingolimod (FTY720) leads to mitigated neuropathy and improved clinical outcome in a mouse model for Charcot-Marie-Tooth 1X disease.

Neuromuscular disorders : NMD
2025

Developing a gene therapy for Charcot-Marie-Tooth disease: progress and challenges.

Regenerative medicine
2025

Reduced elbow muscle strength in children and adolescents with Charcot-Marie-Tooth disease: a case control study.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
2025

A cross-sectional survey on the health status of patients with Charcot-Marie-Tooth disease in a Chinese national patient group.

Journal of neurology
2025

p.M918W, a novel RET germline variant: a case report and literature review of the possible association of multiple endocrine neoplasia type 2B and Charcot-Marie-Tooth disease.

Endocrine journal
2025

Yeast models for Charcot-Marie-Tooth disease-causing aminoacyl-tRNA synthetase alleles reveal the cellular basis of disease.

IUBMB life
2025

Advances in modeling the Charcot-Marie-Tooth disease: Human induced pluripotent stem cell-derived Schwann cells harboring SH3TC2 variants.

European journal of cell biology
2025

The Balance of MFN2 and OPA1 in Mitochondrial Dynamics, Cellular Homeostasis, and Disease.

Biomolecules
2025

Repeated clear benefits of immunotherapy in a patient with Charcot-Marie-Tooth disease carrying a rare point mutation in PMP22.

Neurogenetics
2025

A cellular assay to determine the fusion capacity of MFN2 variants linked to Charcot-Marie-Tooth disease of type 2 A.

Scientific reports
2025

Guillain-Barré syndrome in patients with Charcot-Marie-Tooth type 1A disease, probably a non-random association.

Neurophysiologie clinique = Clinical neurophysiology
2025

A dose escalation and safety study of AAVrh10-mediated Schwann cell-targeted gene therapy for CMT1X.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
2025

BIN1 reduction ameliorates DNM2-related Charcot-Marie-Tooth neuropathy.

Proceedings of the National Academy of Sciences of the United States of America
2025

Outcomes of Triceps Surae Lengthening Surgery in Children With Charcot-Marie-Tooth Disease: A Multisite Investigation.

Journal of pediatric orthopedics
2025

A case report of a MODY6 patient coexistence with Charcot-Marie-Toothe 1A syndrome.

Frontiers in endocrinology
2025

Charcot-Marie-Tooth disease: a review of clinical developments and its management - What's new in 2025?

Expert review of neurotherapeutics
2025

Generation of two induced pluripotent stem cell lines from Charcot-Marie-Tooth type 1B patients harboring autosomal dominant mutations in myelin protein zero gene.

Stem cell research
2025

Activation of XBP1s attenuates disease severity in models of proteotoxic Charcot-Marie-Tooth type 1B.

Brain : a journal of neurology
2025

Genetic landscape of Charcot-Marie-Tooth disease in Vietnam: A prospective multicenter study.

Journal of neuromuscular diseases
2025

RNA Interference Targeting Small Heat Shock Protein B8 Failed to Improve Distal Hereditary Motor Neuropathy in the Mouse Model.

The journal of gene medicine
2025

Unraveling the Genetic Landscape of Foot Arch Morphology: A Systematic Review of Single Nucleotide Polymorphisms.

Clinical genetics
2025

Two novel SH3TC2 mutations predispose to Charcot-Marie-Tooth disease type 4C by mistargeting away from TFRC.

Cellular signalling
2025

Twelve-month change in quantitative MRI calf muscle fat fraction in CMT1A predicts clinical change over 4 years.

Annals of clinical and translational neurology
2025

[Analysis of clinical and novel gene mutations with X-linked Charcot-marie-tooth disease type 1].

Zhonghua yi xue za zhi
2025

Disease Progression in Charcot-Marie-Tooth Disease Type 4B (CMT4B) Associated With Mutations in Myotubularin-Related Proteins 2 and 13.

European journal of neurology
2025

Addressing myelination disorders: Novel strategies using human 3D peripheral nerve model.

Brain research bulletin
2025

Genotype and phenotype spectrum of Charcot-Marie-Tooth disease due to mutations in SORD.

Brain : a journal of neurology
2025

Talar Morphology of Charcot-Marie-Tooth Patients With Cavovarus Feet.

Foot &amp; ankle international
2025

Charcot Marie Tooth disease pathology is associated with mitochondrial dysfunction and lower glutathione production.

Cellular and molecular life sciences : CMLS
2024

First Case of Macrocephaly, Dysmorphic Facies, and Psychomotor Retardation Harboring Co-inherited Variants in HERC1 and PMP22 Genes from Iran: Two Novel Variants.

Archives of Iranian medicine
2025

Hip Dysplasia in Charcot-Marie-Tooth Disease: Insights From a Large Cohort of Children and Adolescents.

Journal of the peripheral nervous system : JPNS
2025

Therapeutic potential of siRNA PMP22-SQ nanoparticles for Charcot-Marie-Tooth 1A neuropathy in rodents and non-human primates.

International journal of pharmaceutics
2025

Phosphodiesterase 4D inhibition improves the functional and molecular outcome in a mouse and human model of Charcot Marie Tooth disease 1 A.

Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie
2025

IP3 receptor depletion in a spontaneous canine model of Charcot-Marie-Tooth disease 1J with amelogenesis imperfecta.

PLoS genetics
2024

A Role of Inflammation in Charcot-Marie-Tooth Disorders-In a Perspective of Treatment?

International journal of molecular sciences
2025

Schwann Cells in Neuromuscular Disorders: A Spotlight on Amyotrophic Lateral Sclerosis.

Cells
2025

[Genetic analysis of a Chinese pedigree affected with Charcot-Marie-Tooth type 2A2A due to a missense variant of MFN2 gene].

Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
2025

Surgical correction of cavus foot may promote quality of life in patients with Charcot-Marie-Tooth disease: A retrospective study.

The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons
2025

Delineating the genetic landscape of Charcot-Marie-tooth disease in Türkiye: Distinct distribution, rare phenotypes, and novel variants.

European journal of neurology
2024

A Novel GBF1 Variant in a Charcot-Marie-Tooth Type 2: Insights from Familial Analysis.

Genes
2025

Foot orthosis design for children with Charcot-Marie-Tooth and impact on gait.

Prosthetics and orthotics international
2024

Charcot-Marie-Tooth Disease Presenting in the Postpartum Period: A Case Report.

Cureus
2025

Novel biallelic nonsense mutation in IGHMBP2 gene linked to neuropathy (CMT2S): A comprehensive clinical, genetic and bioinformatic analysis of a Turkish patient with literature review.

Brain &amp; development
2025

Autophagy induction by piplartine ameliorates axonal degeneration caused by mutant HSPB1 and HSPB8 in Charcot-Marie-Tooth type 2 neuropathies.

Autophagy
2025

CMT2 and distal hereditary motor neuropathy associated with VRK1 variants: Case series.

Neuromuscular disorders : NMD
2025

Neuromuscular transmission deficits in patients with CMT and ClC-1 inhibition in CMT animal models.

Annals of clinical and translational neurology
2025

Electrical impedance myography detects progressive pathological alterations in the hindlimb muscle of the PMP22-C3 mice, an animal model of CMT1A.

Experimental neurology
2024

A fully human IgG1 antibody targeting connexin 32 extracellular domain blocks CMTX1 hemichannel dysfunction in an in vitro model.

Cell communication and signaling : CCS
2025

Neurogenic disease with high CK: think muscle.

Practical neurology
2025

How hidden is hidden hearing loss? Self-reported listening problems in charcot Marie tooth disease.

Journal of communication disorders
2024

Functional ultrasound and brain connectivity reveal central nervous system compromise in Trembler-J mice model of Charcot-Marie-Tooth disease.

Scientific reports
2024

A Review of Muscle Relaxants in Anesthesia in Patients with Neuromuscular Disorders Including Guillain-Barré Syndrome, Myasthenia Gravis, Duchenne Muscular Dystrophy, Charcot-Marie-Tooth Disease, and Inflammatory Myopathies.

Medical science monitor : international medical journal of experimental and clinical research
2024

Co-occurrence of Charcot-Marie-Tooth disease type 1 and glomerulosclerosis in a patient with a de novo INF2 variant.

BMC nephrology
2024

Genetically confirmed Charcot-Marie-Tooth disease type 2A manifesting with postural tremor: a case report.

Journal of medical case reports
2024

A familial form of Charcot-Marie-Tooth disease (type 2d) caused by a previously unreported variant in GARS1.

Journal of neurogenetics
2024

Small Complex Rearrangement in HINT1-Related Axonal Neuropathy.

Genes
2024

Hereditary Neuromuscular Disorders in Reproductive Medicine.

Genes
2024

Regulation of formin INF2 and its alteration in INF2-linked inherited disorders.

Cellular and molecular life sciences : CMLS
2024

Clinical Outcome Assessments and Biomarkers in Charcot-Marie-Tooth Disease.

Neurology
2025

Phenotype-genotype correlation in X-linked Charcot-Marie-Tooth disease: A French cohort study.

European journal of neurology
2024

Synergistic effect of Wharton's jelly-derived mesenchymal stem cells and insulin on Schwann cell proliferation in Charcot-Marie-Tooth disease type 1A treatment.

Neurobiology of disease
2024

INF2 mutations cause kidney disease through a gain-of-function mechanism.

Science advances
2024

Middle ear cholesteatoma and facial nerve hypertrophy mimicking schwannoma in Charcot-Marie-Tooth disease: A case report.

Medicine
2024

Transfer RNA supplementation rescues HARS deficiency in a humanized yeast model of Charcot-Marie-Tooth disease.

Nucleic acids research
2024

Physical exercise halts further functional decline in an animal model for Charcot-Marie-Tooth disease 1X at an advanced disease stage.

Journal of the peripheral nervous system : JPNS
2025

Aminoacyl-tRNA synthetase defects in neurological diseases.

IUBMB life
2025

Postural balance and visual dependence in patients with demyelinating neuropathies differ between acquired and hereditary etiologies.

Revue neurologique
2025

Ighmbp2 mutations and disease pathology: Defining differences that differentiate SMARD1 and CMT2S.

Experimental neurology
2024

Establishment of a human induced pluripotent stem cell (iPSC) line (JUCTCi018-A) from a patient with Charcot-Marie-Tooth disease type 2EE (CMT2EE) due to a homozygous c.122G > A p.(Arg41Gln) mutation in the MPV17 gene.

Stem cell research
2024

Establishment and characterization of three human pluripotent stem cell lines from Charcot-Marie-Tooth disease Type 4B3 patients bearing mutations in MTMR5/Sbf1 gene.

Stem cell research
2024

FIG4-Related Parkinsonism and the Particularities of the I41T Mutation: A Review of the Literature.

Genes
2024

Monitoring Myelin Lipid Composition and the Structure of Myelinated Fibers Reveals a Maturation Delay in CMT1A.

International journal of molecular sciences
2024

Evaluation of the Role of Tanshinone I in an In Vitro System of Charcot-Marie-Tooth Disease Type 2N.

International journal of molecular sciences
2024

Comparison of Manual vs Artificial Intelligence-Based Muscle MRI Segmentation for Evaluating Disease Progression in Patients With CMT1A.

Neurology
2024

Novel Missense Mutation in GJB1 Gene Leading to X-linked Charcot-Marie-Tooth Disease in Young Male: A Case Report.

Neurology India
2024

3D-printed custom ankle braces for people with Charcot-Marie-Tooth disease: A pilot study.

Journal of foot and ankle research
2025

Top 10 Clinical Pearls in Inherited Neuropathies.

Seminars in neurology
2024

Pharmacologically increasing cGMP improves proteostasis and reduces neuropathy in mouse models of CMT1.

Cellular and molecular life sciences : CMLS
2024

Translating a Clinical Practice Guideline to a Portuguese, Spanish and English Practice Brief to promote exercise therapy for paediatric Charcot-Marie-Tooth disease.

Physiotherapy
2024

Effect of Pathogenic Mutations on the Formation of High-Order Dynamin 2 Assemblies in Living Cells.

Biochemistry
2024

Patient-reported disease burden in the Accelerate Clinical Trials in Charcot-Marie-Tooth Disease Study.

Journal of the peripheral nervous system : JPNS
2024

Characterization of a novel heterozygous variant in the histidyl-tRNA synthetase gene associated with Charcot-Marie-Tooth disease type 2W.

IUBMB life

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Doença de Charcot-Marie-Tooth/neuropatia sensitiva e motora hereditária.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Doença de Charcot-Marie-Tooth/neuropatia sensitiva e motora hereditária

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ordenadas pelo número de sintomas em comum.

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Gait Parameters Alterations Under Dual-Task Conditions in Patients With Acquired and Hereditary Peripheral Neuropathies.
    European journal of neurology· 2026· PMID 41873949mais citado
  2. Development and Validation of a Visual Grading Score of Disease Severity From Gait Videos in Genetic Peripheral Neuropathy.
    European journal of neurology· 2026· PMID 41860147mais citado
  3. AAVrh74.tMCK.NT-3 Surrogate Gene Therapy in a Mouse Model of CMT2A.
    International journal of molecular sciences· 2026· PMID 41752078mais citado
  4. Muscle-Specific DNM2 Overexpression Improves Charcot-Marie-Tooth Disease In Vivo and Reveals a Narrow Therapeutic Window in Skeletal Muscle.
    International journal of molecular sciences· 2026· PMID 41683892mais citado
  5. Stress-Driven Selective Neuronal Vulnerability in Charcot-Marie-Tooth Disease: From Prodromal Pathology to Therapeutic Implications.
    Cells· 2026· PMID 41677634mais citado
  6. Characterizing individuals with elevated sweat chloride results in the absence of CFTR variants.
    Orphanet J Rare Dis· 2025· PMID 41318507recente
  7. Evaluation and study of adverse reactions to imiglucerase based on the FAERS database.
    Orphanet J Rare Dis· 2025· PMID 40775785recente
  8. Usefulness of levels of 2-methylbutyrylglycine and 2-ethylhydracrylic acid in urine for diagnosing 2-methylbutyrylglycinuria.
    Orphanet J Rare Dis· 2025· PMID 40598537recente
  9. The RaDiCo information system for rare disease cohorts.
    Orphanet J Rare Dis· 2025· PMID 40200372recente
  10. A healthcare claims analysis to identify and characterize patients with suspected X-Linked Myotubular Myopathy (XLMTM) in the Brazilian Healthcare System.
    Orphanet J Rare Dis· 2024· PMID 38715109recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:166(Orphanet)
  2. MONDO:0015626(MONDO)
  3. GARD:6034(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Artigo Wikipedia(Wikipedia)
  7. Q1052687(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Doença de Charcot-Marie-Tooth/neuropatia sensitiva e motora hereditária
Compêndio · Raras BR

Doença de Charcot-Marie-Tooth/neuropatia sensitiva e motora hereditária

ORPHA:166 · MONDO:0015626
Prevalência
1-5 / 10 000
Herança
Autosomal dominant, Autosomal recessive, X-linked dominant, X-linked recessive
CID-11
Medicamentos
6 registrados
Início
All ages
Prevalência
25.0 (Europe)
MedGen
UMLS
C0007959
EuropePMC
Wikidata
Wikipedia
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades